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Summary
Hirschsprung's disease, or aganglionic megacolon, is a common cause of intestinal
obstruction in neonates and is associated with the congenital absence of intrinsic
ganglion cells in the myenteric and submucosal plexuses of the gastrointestinal tract.
The affected area is usually restricted to the distal part of the colon (short segment
disease), but total colonic or intestinal involvement occurs in some patients (long
segment disease).
DNA analysis was performed on samples from 53 unrelated sporadic HSCR patients
to search for mutations in RET proto-oncogene, endothelin-B receptor (EDNRB) and
endothelin-3 (EDN3) genes. The patients were from different ethnic groups in South
Africa, including 29 coloured, 14 white (Caucasian) and 9 black individuals. The
origin of 1 patient was unknown. PCR HEX-SSCP analysis of the RET proto-
oncogene revealed one previously described (P973L) and five novel mutations
(V202M, E480K, IVS10-2A1G, D771N, IVS19-9Crr), likely to cause or contribute to
the HSCR phenotype. Nine polymorphisms were also identified in the RET proto-
oncogene, of which four were novel (IVS6+56deIG, IVS13-29Crr, IVS16-38deIG,
X1159) and five previously described (A45, A432, L769, S904, R982). All the mobility
shifts detected in the EDNRB gene represented polymorph isms (A60T, S184, 1187,
V234, L277, IVS3-6Crr, IVS4+3A1G). No sequence variants were identified in the
EDN3 gene. The majority of mutations in the RET proto-oncogene (28.6%) were
identified in coloured patients while no mutations were identified in black patients. A
mutation in RET was identified in two of 14 patients (14%) presenting with HSCR and
Down's syndrome compared to 6 mutations identified in 9 of 39 patients (23%) with
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only HSCR. The fact that Down's syndrome patients have a high chance of
developing HSCR, implies the involvement of modifier gene(s) in a HSCR/Oown's
syndrome phenotype.
This study demonstrated that, within the South African HSCR patient population, the
RET proto-oncogene is the major susceptibility gene, whereas EDNRB and EDN3
may contribute only to a minority of cases. In 81% of patients no disease-causing
mutation could be identified, which is in keeping with the heterogeneous nature of
HSCR. The identification of mutations in HSCR patients would in future lead to
improved and accurate counselling of South African HSCR patients and their
families.
Stellenbosch University http://scholar.sun.ac.za
Opsomming
Hirschsprung se siekte (HSCR), ook bekend as aganglionosis megakolon, is 'n
algemene oorsaak van intestinale obstruksie in pasgeborenes en word geassosieer
met die kongenitale afwesigheid van intrinsieke ganglion selle, in die miênteries en
submukosa pleksus van die gastrointestinale kanaal. Alhoewel die aangetaste deel
hoofsaaklik by die distale area van die kolon geleê is (kort segment siekte), kom
totale koloniese of intestinale betrokkenheid ook in sommige pasiënte voor (lang
segment tipe).
Molekulêre ONS analise van 53 nie-verwante Suid Afrikaanse sporadiese HSCR
pasiênte (29 kleurlinge, 14 blankes, 9 swartes en 1 individu van onbekende
oorsprong) is uitgevoer in die RET proto-onkogeen, endoteel-B reseptor (EDNRB) en
endoteel-3 (EDN3) gene. Heterodupleks-enkel string konformasie polimorfisme
(HEX-SSCP) analise van polimerase ketting reaksie (PKR) geamplifiseerde produkte
van die RET proto-onkogeen het gelei tot die identifikasie van vyf nuwe mutasies
(V202M, E480K, IVS10-2A1G, D771N, IVS19-9CIT) en een bekende mutasie
(P973L). Vier nuwe polimorfismes (IVS6+56deIG, IVS13-29Crr, IVS16-38deIG,
X1159) en vyf bekende polimorfismes (A45, A432, L769, S904, R982) is ook
aangetoon. Sewe polimorfismes (A60T, S184, 1187, V234, L277, IVS3-6CIT,
IVS4+3A1G)is in die EDNRB geen geïdentifiseer. Geen veranderinge is in die EDN3
geen waargeneem nie. Die meerderheid mutasies waargeneem in die RET proto-
onkogeen is in die kleurling populasie (28.6%) waargeneem, terwyl geen mutasies in
die swart populasie geïdentifiseer is nie. 'n RET mutasie is in twee van 14 (14%)
pasiênte met In HSCR en Down's sindroom fenotipe waargeneem, in vergelyking met
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6 mutasies geïdentifiseer in 9 van 39 pasiënte (23%) met slegs HSCR. Die algemene
voorkoms van Down's sindroom met HSCR, impliseer die rol van ander gene in die
HSCRIDown's sindroom fenotipe.
Die meerderheid mutasies wat aanleiding gee tot die HSCR fenotipe kom voor in die
RET proto-onkogeen (19%), terwyl slegs polimorfismes in die EDNRB geen
waargeneem is. Geen HEX-SSCP bandpatroon veranderinge is in die EDN3 geen
waargeneem nie. Ongeveer 81% van die Suid Afrikaanse HSCR pasiënte was
mutasie-negatief wat dui op die heterogene aard van die siekte. In die toekoms sal
analise van siekte-verwante mutasies in die RET geen lei tot akkurate diagnose en
verbeterde genetiese voorligting van HSCR in die Suid-Afrikaanse populasie.
Stellenbosch University http://scholar.sun.ac.za
To my mother ...
Stellenbosch University http://scholar.sun.ac.za
ACKNOWLEDGEMENTS
I would like to acknowledge the following persons and institutions without whom this study
would not have been possible;
The Harry and Doris Crossley research fund is gratefully acknowledged for financial support.
The University of Stellenbosch and the Cape Provincial Administration for supplying the
necessary equipment and facilities.
The Red Cross Children's Hospital for supplying tissue samples of the patients used in this
study.
Prof. S. W. Moore, my supervisor, for his enthusiasm for this project and interesting clinical
discussions.
Dr. M. J. Kotze, my co-supervisor, for editing this thesis and for her continuous support and
insight into this project.
Ms L. du Plessis, my co-supervisor, for her assistance on this project and editing this thesis.
Dr. R. Hillermann, for editing this thesis.
My family, for supporting me in my studies.
My partner and soulmate, Elmo, for understanding and supporting me throughout this
degree, and most of all for believing in me.
Stellenbosch University http://scholar.sun.ac.za
TABLE OF CONTENTS
CHAPTER 1. INTRODUCTION
1.1. Background 2
1.2. Genetic Risk 4
1.3. Basis of inheritance 5
1.4. Candidate genes for HSCR 6
1.4.1. RET proto-oncogene 6
1.4.1.1. Structure and function of the RET proto-oncogene 6
1.4.1.2. HSCR and the RET proto-oncogene 9
1.4.2. Endothelin-B receptor gene 12
1.4.2.1. Structure and function of the EDNRB gene 12
1.4.2.2. HSCR and the EDNRB gene 14
1.4.3. Endothelin-3 gene 16
1.4.3.1. Structure and function of the EDN3 gene 16
1.4.3.2. HSCR and the EDN3 gene 17
1.4.4. Other genes associated with HSCR 20
1.4.4.1.Glial eel/line-derived neurotrophic factor (GDNF) 20
1.4.4.2. Endothelin-converting enzyme 1 (ECE1) 21
1.4.4.3. Sex dependent Y factor-like homeobox 10 (SOX10) 22
1.5. The association of Down's syndrome with HSCR 23
Stellenbosch University http://scholar.sun.ac.za
1.6. Objectives 24
CHAPTER 2. MATERIALS AND METHODS
2.1. Subjects 26
2.2. Methods
2.2.1. DNA extraction procedures
31
31
2.2.1.1. DNA extraction from formalin-fixed paraffin embedded tissue 31
2.2.1.2. DNA extraction from solid tissue - method 1 32
2.2.1.3. DNA extraction from solid tissue - method 2 33
2.2.1.4. DNA extraction from whole blood 34
2.2.1.5. DNA purification and concentration of paraffin-embedded
DNA samples 35
2.2.2. Polymerase Chain Reaction (PCR) 35
2.2.2.1. Oligonucleotide Primers 35
2.2.2.2. DNA amplification 38
2.2.2.2.1. General PCR 38
2.2.2.2.2. RET proto-oncogene 39
2.2.2.2.3. Endothelin-B receptor gene 41
2.2.2.2.4. Endothelin-3 gene 41
2.2.3. Agarose gel electrophoresis 42
2.2.4. Heteroduplex single-strand conformation polymorphism analysis 42
2.2.5. Automated sequencing 44
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 3. RESULTS
Mutation analysis of the RET proto-oncogene, endothelin-B receptor (EDNRB)
gene and endothelin-3 (EDN3) gene loci in sporadic Hirschsprung's disease
in the South African population. 47
CHAPTER 4. DISCUSSION, CONCLUSION and FUTURE
PROSPECTS
4.1. Discussion 63
4.1.1. RET proto-oncogene 66
4.1.1.1. Extracellular domain 66
4.1.1.1.1. Cad herin-like sequence (exons 2 - 6) 66
4.1.1.1.2. Cystein-rich region (exons 7 - 10) 68
4.1.1.2. Transmembrane domain 68
4.1.1.3. Intracellular domain 69
4.1.1.3.1. Tyrosine kinase domain 1 and 2 69
4.1.2. Endothelin-B receptor and endothelin-3 genes 72
4.1.3. General observations 73
4.2. Conclusion 75
4.3. Future Prospects
CHAPTERS. REFERENCES
76
78
Stellenbosch University http://scholar.sun.ac.za
LIST OF TABLES
CHAPTER 2. MATERIALS AND METHODS
Table 2.1. Classification of HSCR patients 27
Table 2.2. Classification of control patients 28
Table 2.3. Oligonucleotide primers used for DNA amplification of the RET proto-
oncogene 36
Table 2.4. Oligonucleotide primers used for DNA amplification of the endothelin-B
receptor (EDNRB) gene 37
Table 2.5. Oligonucleotide primers used for DNA amplification of the endothelin-3
(EDN3) gene 38
Table 2.6. Annealing temperatures for the RET proto-oncogene 39
Table 2.7. Annealing temperatures for the RET proto-oncogene 40
Table 2.8. Annealing temperatures for the endothelin-3 gene (EDN3) 41
Stellenbosch University http://scholar.sun.ac.za
CHAPTER3.RESULTS
Table 3.1. Potential disease-causing mutations identified in the RET proto-
Oncogene
Table 3.2. Polymorphisms identified in the RET proto-oncogene
Table 3.3. Polymorph isms identified in the EDNRB gene
54
54
56
Stellenbosch University http://scholar.sun.ac.za
LIST OF FIGURES
CHAPTER 1. INTRODUCTION
Figure 1.1. Schematic representation of the structure of the RET proto-
oncogene 8
Figure 1.2.Spectrum of documented mutations in the RET proto-oncogene 11
Figure 1.3. Schematic representation of the structure of the EDNRB gene 13
Figure 1.4. Spectrum of documented mutations in the EDNRB gene 15
Figure 1.5. Schematic representation of the preproendothelin-3 protein 17
Figure 1.6. Spectrum of documented mutations in the EDN3 gene 20
CHAPTER 3. RESULTS
Figure 3.1. Schematic representation of genomic organisation of the RET
proto-oncogene in relation to three distinct functional domains of the
protein 58
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 4. DISCUSSION, CONCLUSION AND FUTURE
PROSPECTS
Figure 4.1. Spectrum of documented mutations in the RET proto-oncogene 65
Figure 4.2. Dimerisationmodel for receptor tyrosine kinase activation 70
Stellenbosch University http://scholar.sun.ac.za
LIST OF ABBREVIATIONS
CIA
CCHS
Cd
cDNA
degrees Celcius
microlitre
microgram per millilitre
units per microlitre
alanine
renal adenocarcinoma cell-line
adenocarcinoma endothelin converting enzyme
ammonium persulphate
anorectal malformation
base-pair
cysteine
calcium
colonic aganglionosis
congenital central hypoventilation syndrome
cadherin-like sequence
complementary deoxyribonucleic acid
centimeter
carboxy-terminus
cysteine-rich region
aspartic acid
double distilled water
distilled water
dimethyl sulfoxide
!-II
IJglml
UIIJI
A (Ala)
ACHN
AECE
APS
ARM
bp
C (Cys)
Ca2+
cm
COOH
Cys
D (Asp)
ddH20
dH20
DMSO
Stellenbosch University http://scholar.sun.ac.za
DNA
dNTP
Dom
E (Glu)
e
ECE1
ECE1CS
EDN1
EDN2
EDN3
EDNRA
EDNRB
EDTA
ENS
ET1
ET2
ET3
EtOH
F (Phe)
F
FCS
FMTC
G (Gly)
g
GDNF
deoxyribonucleic acid
2' -deoxy-nucleoside-5' -triphosphate
dominant megacolon
glutamic acid
extracellular loop
endothelin-converting enzyme 1
endothelin-converting enzyme 1 cleavage site
endothelin-1 gene
endothelin-2 gene
endothelin-3 gene
endothelin-A receptor gene
endothelin-B receptor gene
ethylenediaminetetraacetic acid
enteric nervous system
endothelin-1
endothelin-2
endothelin-3
ethanol
phenylalanine
forward primer
furin cleavage site
Familial medullary thyroid carcinoma
glycine
gram
glial eel/line-derived neurotrophic factor gene
Stellenbosch University http://scholar.sun.ac.za
GDNFR-alpha
H (His)
HEX-SSCP
MITF
ml
mM
glial cell line-derived receptor alpha
histidine
heteroduplex single-strand conformation polymorphism
analysis
high mobility group
Hirschsprung's Disease
isoleucine
intracellular loop
identity-by-descent
lysine
kilobase
kilo Dalton
potassium hydrogen carbonate
leucine
methionine
moles per litre
Multiple endocrine neoplasia type 2A
Multiple endocrine neoplasia type 2B
milligram
magnesium chloride
milligram per millilitre
minutes
microphthalmia associated transcription factor
millilitre
milli-moles per litre
HMG
HSCR
I (lie)
lBO
K (Lys)
kb
kO
KHC03
L (Leu)
M (Met)
M
MEN2A
MEN2B
mg
MgCI2
mg/ml
min
Stellenbosch University http://scholar.sun.ac.za
mRNA
MTC
N (Asn)
NaCI
NaCI04
NH4CI2
NH2
NIH3T3
messenger ribonucleic acid
medullary thyroid carcinoma
asparagine
sodium chloride
sodium perchloride
ammonium chloride
amino-terminus
nm
NIH (USA) ceJlline 3T3
nano meter
proline
short arm of chromosome
polyacrylamide
phosphate buffered saline
polymerase chain reaction
picomole
picomole per microlitre
glutamine
long arm of chromosome
arginine
reverse primer
REarranged during transfection proto-oncogene
9 amino acid C-terminal isoform
43 amino acid C-terminal isoform
51 amino acid C-terminal isoform
revolutions per minute
P (Pro)
p
PAA
PBS
PCR
pmol
prnol/pl
Q (Glu)
q
R (Arg)
R
RET
RET9
RET43
RET51
rpm
Stellenbosch University http://scholar.sun.ac.za
RIS
RTK
RT-PCR
S (Ser)
S
SOS
SH2
SOX10
SP
SRY
SSCP
T (Thr)
Taq
TBE
TCA
TE
TEMEO
TK
Tm
U
UTR
V (Val)
V
vlv
Val
rectosigmoidal aganglionosis
receptor tyrosine kinase
reverse transcriptase polymerase chain reaction
serine
signal sequence
sodium dodecyl sulphate
src homology 2 domain
sex-dependent Y factor-like homeobox 10
signal peptide
sex-dependant Y factor
single-strand conformation polymorphism
threonine
thermus aquaticus
tris-borate/EOT A
total colonic aganglionosis
tris-EOTA
N, N, N' N',-tetramethylethylenediamine
split tyrosine kinase domain
transmembrane domain
units
untranslated region
valine
volts
volume per volume
valine
Stellenbosch University http://scholar.sun.ac.za
W (Trp)
w/v
X (Unk)
Y (Tyr)
tryptophan
weight per volume
unknown
tyrosine
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 1
INTRODUCTION
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21.1. BACKGROUND
Hirschsprung's disease (HSCR) was described by Harald Hirschsprung in 1888 as
congenital megacolon, but only recently, following research, have the pathogenesis
and pathophysiology become more clear. The disease is characterised by the
congenital absence of intrinsic ganglion cells in the myenteric and submucosal
,
plexuses of the gastrointestinal tract, thereby the name aganglionic megacolon. The
main cause of clinical presentation is due to partial or complete intestinal obstruction
during infancy because of a malfunction of the involved segment and adults usually
present with severe constipation. The aganglionic segment is restricted to the distal
part of the colon (rectosigmoidal area) in 75% of cases (short segment disease), to
the sigmoid, splenic flexure or transverse colon in 17% of cases, and to the total
colon plus a short segment of the latter part of the ileum in the remaining 8% of
cases. In the rarest form, total aganglionosis extends from the duodenum to the
rectum. Patients usually present with one or more of the following additional clinical
symptoms: failure to pass meconium, secondary electrolyte disturbances,
megacolon, colonic distension, severe constipation and sepsis due to enterocolitis.
The most common chromosomal abnormality associated with HSCR is Down's
syndrome (Bodian et a/1951), but other chromosomal abberations such as mosaic
trisomy 18 (Passarge 1973), partial trisomy of region 21q22 and 11q23 (Beedgen et
a/1986) and interstitial deletions observed on 13q (Kiss and Osztovics 1989, Bottani
et a/1991) and 10q (Martucciello et a/1992, Luo et a/1993) are also associated with
the disease. Other syndromes associated with HSCR include metaphyseal
chondrodysplasia, McKusick type (McKusick et al 1965), Waardenburg syndrome
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3(Omenn and McKusick 1979), Smith-Lemli-Opitz syndrome type II (Curry et a/1987),
multiple endocrine neoplasia type 2A and 2B, and medullary thyroid carcinomas (Eng
et a/1994). At present, the disease can be diagnosed using a combination of tests,
including rectal manometry, radiological examinations and histological, histochemical
or immunohistochemical analysis of the affected segment (Huntley et a/ 1982,
Molenaar et a/1989). The affected segment is usually removed by surgery by one of
the following procedures: Swenson procedure (Swenson 1950), Duhamel procedure
(Duhamel 1960), Soave procedure (Soave 1960) or the Rehbein procedure (Rehbein
et a/ 1960). Modifications of these procedures included the Martin procedure (Martin
1968), Stringel operation (Stringel 1973), Kimura procedure (Kimura et a/ 1981),
Shand ling operation (Shand ling 1984) and the Boley operation (Boley 1984).
The enteric nervous system originates from neural crest precursor cells which
migrate and colonise the wall of the intestinal tract during embryogenesis. The first
neuroblasts are detected on the 24th gestational day of embryogenesis in the
proximal foregut (Hoar and Monic 1981). The craniocaudal migration occurs during
the 5th to 12th week of gestation (Okamoto and Ueda 1967, Sullivan 1996).
Extracellular matrix proteins, neurotrophic factors and cell adhesion molecules are
important factors required for the developing, differentiation, migration and survival of
neurons in the peripheral and central nervous system (Brauer and Markwald 1987,
Crossin et a/1990, Theonen 1991). The absence of ganglion cells was postulated to
be due to a failure of migration of the neural crest cells and the earlier the arrest, the
longer the aganglionic segment (Okamoto and Ueda 1967). It has therefore been
hypothesised that micro-environmental changes, eg an altered extracellular matrix,
causes failure of cell differentiation and results in aganglionosis (Le Douarin and
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4Teillet 1974, Gershon et al 1980, Greenberg et al 1981). However, recent studies
using mouse models, indicate that the ganglion cells reach the correct position, but
fail to develop or survive, resulting in aganglionosis (Puri et a/1998).
1.2. GENETIC RISK
The involvement of genetic factors in HSCR was suggested due to an increased risk
to siblings and the frequent association of the disease with chromosomal
abnormalities such as Down's syndrome and Waardenburg syndrome. HSCR has an
estimated population incidence of 1 in 5000 (0.02%) live births (Passarge 1967) with
an overall risk to siblings of 4% - 9% (Badner et a/1990). Males are more likely to be
affected than females, with a risk 3.5 - 7.8 fold higher than that of females (Badner et
al 1990). As the aganglionic segment becomes more extensive, the risk to siblings
increases and the sex ratio decreases (1.5 to 2.1, respectively, for males and
females with long segment disease) (Puri 1997). HSCR mostly occurs sporadically
(approximately 90% of cases), with an incidence of 3.6% to 7.8% for familial cases
reported (Ikeda and Goto 1984, Puri 1997) with total colonic aganglionosis occuring
in 15% to 21% of these familial cases (Kleinhaus et a/1979). An earlier age of onset
in the patients is usually associated with a higher risk of disease occurrence in the
siblings (Angrist et a/1993).
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51.3. BASIS OF INHERITANCE
The suspected basis of HSCR was initially believed to be a sex-modified
multifactorial trait (Passarge 1967). The finding that males are more likely to be
affected than females, suggested that the disease is stimulated by an X-linked
recessive trait if transmission is maternal. Consequently, multifactorial inheritance,
with the involvement of multiple genes and environmental factors in the development
of the clinical phenotype, was suggested (Passarge 1967, Garver et al 1985).
However, the observation of multiple chromosome aberrations in HSCR patients,
supported genetic heterogeneity, with autosomal dominant, autosomal recessive and
polygenic forms of inheritance. The occurrence of the disease with chromosomal
abnormalities and congenital anomalies, strengthened this school of thought,
implicating the involvement of a large number of genes, each with a small
cummulative effect (Badner et al 1990). In cases with aganglionosis beyond the
sigmoid colon and in some large pedigrees, the pattern of inheritance was most
compatible with an incomplete penetrant dominant gene (Badner et a/1990).
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61.4. CANDIDATE GENES FOR HSCR
Several genes are involved in the pathogenesis of HSCR, including the REarranged
during transfection proto-oncogene (RET) (Takahashi et al 1985), endothelin-B
receptor gene (EDNRB) (puffenberger et al 1994b), endothelin-3 gene (EDN3)
(Edery et a/1996, Hofstra et al 1996) glial cell line-derived neurotrophic factor gene
(GDNF) (Treanor et al 1996, Jing et al 1996), endothelin-converfing enzyme 1
(ECE1) (Hofstra et al 1999), the sex dependent Y factor-like homeobox 10 gene
(SOX10) (Pingualt et al 1997) and neurfurin (NTN) (Doray et al 1998). The genes
that have been implicated in HSCR are important for the migration of cells originating
from the neural crest and their subsequent development as enteric ganglia, possibly
acting in the signalling pathwaywhich differentiates pre-ganglion cells into maturity.
1.4.1. RET proto-oncogene
1.4.1.1. Structure and function of the RET proto-oncogene
The RET gene was originally identified by Takahashi and colleagues during a classic
NIH 3T3 transformation assay, cloned as a chimeric oncogene (Takahashi et al
1985). RET is expressed in the brain, thymus, lung, heart, spleen, testis and small
intestine of adults, and in embryos, the level of expression is 20-50 fold higher than
that observed in adults (Tahira et al 1988, Hóppener and Lips 1996). These high
embryonic levels reduce to adult levels by day 14 of gestation. The RET proto-
oncogene is a cell-surface molecule that transduces signals for cell growth and
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7differentiation and encodes a putative transmembrane receptor tyrosine kinase
protein.
Five different mRNA species of RET, due to alternative splicing and polyadenylation,
were identified in a human neuroectodermal cell line (Tahira et a/ 1990). These
mRNAs were 7.0 kb, 6.0 kb, 4.6 kb, 4.5 kb and 3.9 kb in size. Two isoforms of RET
were identified: a RET protein consisting of 1072 amino acids (mRNA - 7.0 kb, 4.5
kb and 3.9 kb) and a protein consisting of 1114 amino acids (mRNA - 6.0 kb and 4.6
kb). The first 1063 amino acids are identical in both isoforms and two tyrosine
residues that represent additional autophosphorylation and substrate binding sites,
are included in the larger isoform at the 51 amino acid (RET51) C-terminal. These 51
amino acids are replaced with 9 alternative amino acids (RET9) at the C-terminal in
the shorter isoform to generate a 1072 amino acid protein, resulting from differential
splicing at the 3' end of exon 19 (Tahira et a/1988,1990, Takahashi et a/1988, Kwok
et a/ 1993). The 20 exons of RET were shown, by restriction mapping and Northern
analysis, to be encoded by the 51 amino acid C-terminal isoform, but various lengths
of the 3' untranslated region (UTR) and alternative splicing occur in this area. No
splicing occurs in the 9 amino acid RET isoform, but it includes 9 codons which lie
within intron 19, directly downstream of exon 19 (Tahira et a/1990).
In the characterisation of the 3' region of RET, using cloned cDNA and reverse
transcriptase PCR (RT-PCR), a protein with an alternative 43 amino acid C-terminal
(RET43) was identified (Myers et a/1995). This resulted from splicing of exon 19 to a
previously unrecognised coding exon, exon 21. Alternative splicing was also shown
at the 5' end of the gene which resulted in transcripts lacking exon 3, exons 3 and 4
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8or exons 3, 4 and 5. Two mature RET proteins of 170 kO and 175 kO were generated
when fully glycosylated and were localised to the cell membrane, functioning as cell-
surface receptors. Smaller RET proteins of 150 kO and 155 kO were generated when
partially glycosylated and were localised to the cytoplasm, implicating that they
cannot bind extracellular ligands (Takahashi et al 1991,1993, Bunone et al 1995).
The gene therefore comprises 21 exons (Myers et al 1995) in a genomic region
spanning ± 50 kb with exons varying in size from 60 bp to 287 bp. The RET proto-
oncogene can be divided into different domains as illustrated in Figure 1.1: an
extracellular cad herin-like domain which is encoded by exons 1 to 10, a
transmembrane domain encoded by exon 11 and an intracellular (split tyrosine
kinase) domain encoded by exons 12 to 21. The protein is localised to the cell
membrane and functions as a cell-surface receptor.
Extracellular domain Intracellular domain
OH
S Cd Cys Tm TK1 TK2
Figure 1.1. Schematic representation of the structure of the RET proto-
oncogene. Abbreviations: S - signal sequence, Cd - Cad herin-like sequence,
Cys - Cysteine-rich region, Tm - Transmembrane domain, TK1 and TK2 - Split
tyrosine kinase domain; NH2 - amino-terminus; COOH - carboxy-terminus
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9The hydrophobic signal sequence NH2 -terminus targets the molecule to the cell
surface (Hëppener and Lips 1996). The extracellular domain shows homology to the
cadherin family and consists of highly conserved cysteine residues located close to
the cell membrane. The cysteine residues play a role in ligand binding and
dimerisation. Cadherins are known to be Ca2+ - dependent adhesion molecules which
are involved in cell to cell interactions, but it is not yet known whether they have
similar functions in the RET protein. The hydrophobic Tm anchors the molecule in the
plasma membrane. The intracellular domain consists of the tyrosine kinase regions 1
and 2, which is the most highly conserved area of the gene. The tyrosine kinase
protein regulates the proliferation, migration, differentiation and survival of particular
neural crest cells.
1.4.1.2. HSCR and the RET proto-oncogene
RET plays an important role in the development of neural crest derivatives during the
early stages of embryogenesis. The identification of an interstitial deletion of
chromosome 10 in a patient with long segment disease as well as the identification of
similar deletions in other patients with HSCR implicated chromosome 10 in the
pathogenesis of the disease (Martucciello et al 1992, Luo et al 1993). Families
displaying dominantly inherited HSCR with incomplete penetrance were used to
localise the gene to chromosome 1Oq11.2 by linkage analysis (Luo et al 1993,
Lyonnet et al 1993, Angrist et al 1993). With the cloning of RET (Takahashi et al
1985) and the availability of the DNA sequence of the exon-intron boundaries (Kwok
et a/1993, Ceccherini et al 1993), the identification of mutations affecting different
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domains of the RET gene was facilitated. The involvement of the RET gene in HSCR
pathogenesis was confirmed by the identification of many different variants, including
missense, nonsense, deletion and insertion mutations. These mutations account for
approximately 25% of HSCR cases and are not restricted to a particular area of the
gene as depicted in Figure 1.2 (Edery et a/1994a, Romeo et a/1994, Luo et a/1994,
Attie et al 1995a, Angrist et al 1995, Seri et al 1997).Most HSCR cases occur
sporadically and the frequency of RET gene mutations is higher in familial cases
(28.4%) than in sporadic cases (17.6%). More mutations occur in patients with long
segment disease, even in sporadic cases (see figure 1.2 for details of RET mutations
in HSCR). RET mutations are also associated with diseases such as multiple
endocrine neoplasia type 2A and 28 (MEN 2A and 28), familial medullary thyroid
carcinoma (FMTC), sporadic medullary thyroid carcinomas and pheochromocytoma
and papillary thyroid carcinoma (Eng and Mulligan 1997).
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M980T
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E921X
W942X
5' UTR - 5' untranslated region
--- - point mutations
-7 - point mutations resulting in a termination codon
~ - splice site mutation
_ - deletion mutation
CJ - insertion mutation
.. - complex event involving duplication, insertion and deletion resulting in stoj
codon
Figure 1.2. Spectrum of documented mutations in the RET proto-oncogene (from En~
and Mulligan 1997)
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1.4.2. Endothelin-B Receptor gene
1.4.2.1. Structure and function of the EDNRB gene
Endothelins belong to a family of potent vasoactive peptides consisting of 3
isopeptides, ET1, ET2 and ET3 (Yanagisawa et a/1988). The EDNRB gene has a
genomic span of 24 kb and encodes a 442 amino acid heptahelic receptor that
equally binds EDN-1, 2 and 3 (Arai et a/ 1993). The gene consists of seven exons
divided by six introns that vary in size from 109 bp to 2855 bp and 0.2 to 14.5 kb,
respectively. The gene is relatively conserved between different species.
Each exon encodes several structural units; exon 1 encodes the entire 5'- noncoding
region and the coding region through the second transmembrane domain, exon 2
encodes the first extracellular loop and the third transmembrane domain, exon 3
encodes the second cytoplasmic loop, the fourth transmembrane domain and the
second extracellular loop, exon 4 encodes the fifth transmembrane domain and the
third cytoplasmic loop, exon 5 encodes the sixth transmembrane domain and the
third extracellular loop, exon 6 encodes the seventh transmembrane domain and
exon 7 encodes the cytoplasmic carboxyl tail and the entire 3' - noncoding region
(Figure 1.3.).
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Figure 1.3. Schematic representation of the structure of the EDNRB gene
Abbreviations: Tm - transmembrane domains (1-7), e - extracellular loop, i -
intracellular loop; NH2 - amino-terminus; eOOH - carboxy-terminus.
Each intron lies in close proximity to the putative transmembrane domains which
implies that each exon encodes a functional unit. The fifth transmembrane domain is
important for the ligand-binding characteristics and signal transduction (Becker et al
1994). It has been demonstrated that mutant receptors lead to dysfunctional
signalling pathways, altered processing pathways and faulty translocation (Arai et al
1993).
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1.4.2.2 HSCR and the EDNRB gene
Interstitial deletions of chromosome 13 in patients with HSCR, suggested a role for
chromosome 13 in the pathogenesis of the disease (Sparkes et a/1984, Lamont et al
1989, Kiss and Osztovics 1989, Bottani et a/1991). In 1994 the EDNRB gene was
mapped to the region 13q22 by using identity-by-descent (lBO) and linkage
disequilibrium mapping of a large inbred (Mennonite) kindred with HSCR,
demonstrating autosomal recessive inheritance (puffenberger et al 1994b). A
missense mutation identified in this gene (Trp276Cys) segregated with HSCR in the
Mennonite kindred (puffenberger et al 1994a) and was associated with incomplete
penetrance of the phenotype. EDNRB, identified as the second gene for HSCR, was
subsequently cloned, characterised and the exon-intron boundaries, 5'-flanking
region and the 3'-flanking region were determined (Arai et al 1993). Targeted
disruption of the mouse Ednrb gene resulted in aganglionic megacolon (Hosoda et al
1994, Gariepy et al 1996). These findings established EDNRB as an important
component in the normal development of the enteric ganglion neurons and epidermal
melanocytes (neural crest-derived cell lineages).
The gene encodes a heptahelical receptor protein and the signaling pathway through
this receptor is important for the establishment of the enteric nervous system.
Southern blot analysis indicated that only one copy of the gene exists in the human
genome and the size of the gene corresponds with other G protein-coupled receptor
genes (Arai et a/1993). Mutations identified in the EDNRB gene indicated that males
had a greater risk of being affected than females (puffenberger et a/1994a). EDNRB
mutations account for 5-6% of HSCR cases and the patients with such a mutation
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mutation have aganglionosis restricted to the distal part of the colon (Chakravarti
1996). Figure 1.4 is a schematic representation of the distribution of EDNRB
mutations identified to date. Homozygous mutations of EDNRB have been shown to
contribute to a HSCR-Waardenburg syndrome phenotype, whereas heterozygous
mutations contribute to non-syndromic HSCR with incomplete penetrance (Amiel et
8/1996). This suggested that EDNRB mutations could be dosage sensitive and that
one or more modifier genes are involved in HSCR patients with heterozygous
mutations. Puffenberger et al. (1994a) indicated that homozygotes and
heterozygotes for the EDNRB mutation identified in the Mennonite family, had a 74%
and 21% risk, respectively, of developing HSCR. In certain studies a loss-of-function
or dysfunction of the EDNRB gene was indicated in isolated HSCR cases (Kusafuka
et 8/1996, Auricchio et a/1996, Svensson ef a/1999).
G57S
M3741
R319W N3781
383L
390R
C109R
W275X
point mutation
~ - point mutation resulting in termination codon
- deletion mutation
c::::J insertion mutation
Figure 1.4. Spectrum of documented mutations in the EDNRB gene
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1.4.3. Endofhelin-3 gene
1.4.3.1. Structure and function of the EDN3 gene
The endothelins are encoded in prepropolypeptide precursors and are produced from
the precursor through its intermediate. The precursors are first cleaved by furin at
tetrapeptide recognition sites (Barr 1991, Seidah and Chretien 1992). The cleavage
produces big endothelin, a biologically inactive intermediate, which contains 41
amino acids in humans (Arinami et a/1991, Kusafuka and Puri 1998). Big endothelin
is then further cleaved at the Trp-21-Val/lle-22 site by endothelin-converting enzyme
1 (ECE1), a metalloprotease. This produces the mature form of EDN3. A second
cleavage site for furin also occurs after the big EDN3 sequence.
The mRNA of EDN3 encodes a 230 amino acid precursor that includes EDN3 and a
15 amino acid homologous segment called the EDN3-like sequence. The
preproendothelin-3 gene comprises 5 exons and 4 introns. The regions encoding big
EDN3 and EDN3-like peptides show 50% to 60% homology to EDN1 and EDN2.
Exon 2 encodes the mature endothelin portion and the tail portion of big EDN3 is
encoded by exons 2 and 3 (Arinami et al 1991). Strong conservation of the
nucleotide sequence that encodes the mature endothelin-3 gene (21 amino acids) is
observed. Exon 3 encodes the EDN3-like peptides in which the relative positions of
the four cysteine residues are perfectly conserved. Figure 1.5 provides a
representation of the EDN3 gene.
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Figure 1.5. Schematic representation of the preproendothelin-3 protein.
Abbreviations: SP- signal peptide, EDN3 - mature EDN3, FCS- furin cleavage
site, ECE1CS- endothelin-converting enzyme 1 cleavage site
When EDN3 activates EDNRB (a G protein-coupled receptor), it induces the flow of
calcium into the cell (puffenberger et a/1994a). Both genes were identified on enteric
neurons and gut mesenchyme cells of human fetuses, which suggested that the
function of EDN3 and EDNRB could be the regulation of interactions between neural
crest cells and gut mesenchyme cells that are required for normal neural crest
migration (Robertson et a/1997).
1.4.3.2HSCRand the EDN3 gene
Endothelins (potent vasoactive peptides) act on G protein-coupled heptahelical
receptors and consists of 21 amino acid peptides. Three mammalian endothelins
have been identified, EDN1, EDN2 and EDN3, and are encoded by separate genes
(Rubanyi and Polokoff 1994). Endothelin-A receptor (EDNRA) and endothelin-B
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receptor (EDNRB) are two subtypes which act as receptors for the endothelins (Arai
et a/ 1990, Sakurai et a/ 1990, Sakamoto et a/ 1993). EDN1 has a high affinity for
EDNRA, whereas EDNRB binds equally to these endothelins (Yanagisawa 1994).
A targeted disruption of the murine endothe/in-3 ligand gene showed a recessive
phenotype of megacolon and coat colour spotting, as observed in mouse-models of
the Ednrb gene (Baynash et a/1994). No abnormalities were observed in mice with
heterozygous mutations of the EDN3 gene. These studies indicated that EDN3 plays
an important role in the normal development of epidermal and choroidal melanocytes
and enteric ganglion cells, and that the signal conveyed by EDN3 through EDNRB is
required for the development of these cells. Although EDNRB binds equally to EDN1
and EDN2, the study indicated normal levels of these endothelins in homozygous
knockout Edn3/Edn3 mice. This implies that these endothelins cannot compensate
for the function of EDN3 and therefore EDN1 and EDN2 do apparently not playa role
in the development of the two cell lineages.
EDN3 mRNA is mainly expressed in the jejenum and adrenal gland, and to a lesser
extent in the brain, spleen and renal medulla (Arinami et a/1991). The EDN3 locus
was assigned to chromosome 20 by analysing genomic DNA from human-mouse
somatic cell hybrids (Bloch et a/ 1989a, 1989b). The gene was further localised to
chromosome region 20q13.2-q13.3 by in situ hybridisation (Gopal Rao et a/1991,
Arinami et a/1991). Mutations identified in the EDN-3 gene in HSCR patients have
contributed to elucidating the involvement of the gene in disease pathogenesis
(Edery et a/1996, Hofstra et a/1996). Thus far, only homozygous mutations have
been identified in patients with syndromic HSCR (Shar-Waardenburg syndrome)
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(Hofstra et a/1996, Kusafuka and Puri 1998, Edery et a/1996). Figure 1.6 provides a
summary of mutations identified in the EDN3 gene. No heterozygous mutations have
been identified in HSCR and non-syndromic HSCR patients. Relatives of individuals
with homozygous EDN3 mutations, show heterozygous mutations with no phenotype
of either HSCR or Waardenburg syndrome (Svennson et a/ 1999). Similar
heterozygous mutations have however been found in individuals with isolated HSCR
or congenital central hypoventilation syndrome (CCHS) (Bolk et a/1996a). Svennson
and colleagues (1999) postulated that the difference in phenotypic expression could
be due to reduced penetrance of some EDN3 mutations and/or accessory mutations
in modifier genes. To date no mutations in other HSCR genes (RET and EDNRB)
have been reported in combination with EDN3 mutations.
C159F A224T
A17T
3'5'
2 5
E198X
-- - point mutations
~ - point mutation resulting in a termination codon
Figure 1.6. Spectrum of documented mutations in the EDN3 gene
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1.4.4. OTHER GENES ASSOCIATED WITH HSCR
1.4.4.1. Glial cel/line-derived neurotrophic factor (GDNF)
GDNF was identified in 1996 as one of the ligands of the RET proto-oncogene, which
encodes a tyrosine kinase receptor (Treanor et al 1996, Jing et al 1996). The gene,
an extracellular neurotrophic molecule localised to chromosome 5p12-p 13.1
(Schindelhauer et a/1995), acts as a ligand for a multisubunit receptor in which the
glycosylphosphatidylinositol-linked protein GDNFR-alpha provides ligand-binding and
the signaling components are provided by RET. Previous studies have shown that in
the absence of GDNF or GDNFR-alpha, RET signalling is reduced or absent
(Treanor et al 1996, Robertson et al 1997). Total intestinal obstruction was also
observed in mice carrying two null alleles for Gdnf (Sanchez et al 1996). These
studies suggested that neurons of the enteric nervous system (ENS), in the absence
of GDNF, die during late embryonic development. Receptor tyrosine kinase converts
extracellular information into chemical signals that can be transduced inside the cell
(Martucciello et al 1995), including binding of GDNF as a dimer in which GDNFR-
alpha is involved, receptor dimerisation, activation of tyrosine kinase and
transphosphorylation of intracellular protein targets. Alterations in this signaling
pathway have been postulated to result in a HSCR phenotype. The GDNF mature
protein consists of 134 amino acids and is encoded by two exons consisting of 151
bp and 485 bp, respectively. GDNF mutations identified in HSCR patients range in
frequency from 0.9% to 5.5% (Angrist et a/1996, Salomon et a/1996, Ivanchuk et al
1996). Studies performed by Angrist et al (1996) and Salomon et al (1996) have
suggested that GDNF mutations are not sufficient to cause HSCR per se, but their
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interaction with other susceptibility loci, such as RET, could contribute to HSCR
susceptibility. Overall, GDNF contributes to only a minority of HSCR cases and its
function can be compensated for by other neurotrophic factors through other
pathways (Angrist et a/1996, Salomon et a/1996).
1.4.4.2. Endothe/in-converting enzyme 1(ECE1)
Mice with Ece1 deficiencies lack enteric neurons and epidermallchoriodal
melanocytes, reproducing the phenotype of endothelin-3 and Ednra knockout mice
(Yanagisawa et a/1998). The ECE1 gene locus was mapped to chromosome 1p36.1
by isotopic in situ hybridisation, and comprises 19 exons in a genomic region of 68 kb
(Valdenaire et a/1995, Matsuoka et a/1996, Albertin et a/1996). The enzyme is a
zinc-chelating metalloprotease containing the typical HEXXH (HELTH) motif (Schmidt
et a/1994). The complete cDNA of human ECE was isolated by RT-peR and cDNA
screening. Human ECE cDNA was also obtained by screening an ACHN human
renal adenocarcinoma library, referred to as AECE, encoding a 770-codon open
reading frame (Yorimitsu et a/1995). This sequence differs at the amino end from the
sequence isolated by Schmidt et a/ (1994) with a similarity of 96% between the
amino acids of rat ECE and human AECE. Endothelin 1, -2 and -3, encoded by the
genes EDN1, EDN2 and EDN3, respectively, are catalyzed by ECE1 enzyme from
their inactive form to their biologically active peptides, ET1, ET2 and ET3. The
involvement of the ECE1 gene in Hirschsprung's disease was indicated by the
presence of a C to T transition, resulting in the substitution of cysteine for arginine at
position 742 (Hofstra et a/ 1999) in a single individual. This mutation is in close
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proximity to the active site of ECE1 (Valdenaire et al 1995) and appears to be
responsible or at least contributed to the patient's phenotype (Hofstra et a/1999).
1.4.4.3. Sex dependent Y factor-like homeobox 10gene (SOX 10)
Research on mice, performed at the Jackson Laboratory (Lane and Liu 1984)
demonstrated that Doml+ heterozygous mice (Dam - dominant megacolon) had
regional deficiencies of neural crest - derived enteric ganglia in the distal colon and
that Dam/Dam homozygous mice were embryonic lethal. The Dam gene in mice is
located in the mid-terminal region of mouse chromosome 15 and synteny was shown
between the Dom locus and human chromosome 22q12-q13 (Pingualt et al 1997).
By positional cloning, SOX 10 was considered a candidate gene for the DaM locus
(Southard-Smith et a/1998). Futher studies demonstrated that SOX 10 is essential
for the proper development of the peripheral nervous system in mice (Herbarth et al
1998). The SOX gene family consists of genes related to SRY, the testis-determining
gene, with more than 60% sequence identity with SRY HMG (high mobility group)
box. The Sox 10 gene of rats was cloned and expression was demonstrated mainly
in the glial cells of the nervous system (Kuhlbrodt et a/1998). The gene comprises 5
exons and spans a region of 14 kb of genomic DNA. A role for SOX 10 in conferring
cell specifity to the function of other transcription factors in developing and mature
glia was proposed by Kuhlbrodt et al (1998). SOX 10 was therefore considered a
likely candidate gene for HSCR, especially since it is associated with features of
Waardenburg syndrome (Southard-Smith et a/1998, Herbarth et al 1998). Recently,
mutations of the SOX 10 gene have been identified in four families with Shah-
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Waardenburg syndrome, which resulted in haploinsufficiency of the SOX 10 product
(Pingualt et a/1998, Kuhlbrodt et a/1998).
1.5. THE ASSOCIATION OF DOWN'S SYNDROME WITH HSCR
HSCR has been found to be associated with Down's syndrome (mongolism) (Bodian
et al 1951), which occurs in 2% to 15% of all HSCR cases (Puri 1993, Polly and
Coran 1993). These patients present with symptoms including constipation, neonatal
intestinal obstruction, abdominal distension, enterocolitis and meconium plug
syndrome (Moore and Johnson 1998). The mean maternal and paternal age of 33.5
and 37.4 years, respectively are significantly higher in patients with both HSCR and
Down's syndrome compared with patients with only HSCR and control patients
(mean maternal age = 26.6 years, mean paternal age = 29.2 years) (Garver et al
1985). The consistent association of HSCRwith Down's syndrome suggests a role of
chromosome 21 in the pathogenesis of the disease (Passarge 1967). Emanuel et al
(1965) postulated that the gene involved in HSCR could be located on chromosome
21 or that abnormalities associated with Down's syndrome could, in the embryonic
period, provide an alternative mechanism which results in HSCR. Studies performed
using identity-by-descent (lBO) analysis and linkage disequilibrium in a Mennonite
kindred revealed preliminary evidence of a genetic modifier for HSCR on
chromosome 21q22 (puffenberger et al 1994b). In another instance a case of
leukocyte adhesion deficiency (LAD) resulting from a deletion on chromosome 21
was associated with a HSCR-like presentation (Rivera-Matos et al 1995). LAD has
been mapped to the region encoding CD18 on chromosome 21 and localised to
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21q22.1-qter and q22.3 (Petersen et a/1991). This coincides with the same area that
was suggested by Puffenberger et a/ (1994b) for a modifier gene that could be
involved in HSCR.
1.6. OBJECTIVES
The aim of this study was to screen for RET-, EDNRB- and EDN3 gene mutations in
HSCR and Down's syndrome patients (with HSCR). The identification of novel
mutations in these genes may broaden our understanding of their biological role in
differentiation of cells of neural crest origin. Patients with a family history of HSCR
could thereafter be selected for mutation screening. This would lead to improved
counseling of families and individuals at risk of developing HSCR.
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CHAPTER 2
SUBJECTS AND METHODS
Detailed experimental procedures
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2.1. SUBJECTS
The study cohort included subjects from different ethnic groups in South Africa:
coloureds, blacks and whites. In this study "white" refers to an individual of European
descent, mainly Dutch, French, German and British stock; "coloured" refers to an
individual of mixed ancestry, including San, Khoi, African Negro, Madagascar,
Javanese and European origin; "black" refers to South Africans of central African
descent. Colonic tissue samples were obtained from 53 clinically diagnosed HSCR
patients, including 41 frozen tissue samples and 12 formalin-fixed paraffin embedded
samples (Table 2.1). HSCR occurred sporadically in these patients. Three of these
patients have total colonic aganglionosis (6%), four have colonic aganglionosis (7%)
and the remaining forty-six patients (87%) have short segment disease. Fourteen of
the patients with short segment disease were also clinically diagnosed with Down's
syndrome. Both the ganglionic and aganglionic tissue samples for four of these
patients were also included. The control samples comprised 6 anorectal
malformations and 24 normal colonic tissue samples, including 17 formalin-fixed
paraffin embedded samples and 13 frozen tissue samples, and 56 randomly chosen
blood samples (Table 2.2).
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Table 2.1. Classification of HSCR patients
ID Sex Race Extent of Additional Clinical SECTION OBTAINED
aganglionosis Features
H1 M C RIS Rectosigmoid colon
H4 M W RIS Rectosigmoid colon
H5 M W CIA Colon
H7 M C RIS Rectosigmoid colon
H9 M B CIA Colon
H10 M B RIS Rectosigmoid colon
H11 M C TCA Colon
H13 M C RIS Upper Rectum
H14 M C RIS Rectosigmoid colon
H15 M C RIS Rectosigmoid colon
H17 F C RIS Rectosigmoid colon
H18 M C RIS Rectosigmoid colon
H19 M B RIS Rectosigmoid colon
H2O U U RIS Rectosigmoid colon
H21 M C RIS 15cm aganglionosis Rectal Biopsy
H23 M W RIS Down Syndrome Rectosigmoid colon
H25 M B RIS Rectosigmoid colon
H26 F C RIS Rectosigmoid colon
H27 M B RIS Rectosigmoid colon
H28 M W TCA Colon
H29 M C RIS Rectosigmoid colon
H33 M B CIA Colon
H34 M W RIS Rectal Biopsy
H37 M C RIS Rectosigmoid colon
H38 M C RIS Rectal Biopsy
H39 M C RIS Rectosigmoid colon
H40 M C RIS Rectosigmoid colon
H41 F C RIS Rectosigmoid colon
H42 F C CIA Colon
H44 F C RIS Down Syndrome Rectosigmoid colon
H63 M C RIS Rectosigmoid colon
H64 M W RIS Rectosigmoid colon
H65 M B TCA Colon
H66 F C RIS Rectosigmoid colon
H67 M B RIS Rectosigmoid colon
H68 M C RIS Rectosigmoid colon
H69 M W RIS Rectosigmoid colon
H70 F C RIS Rectosigmoid colon
H71 M B RIS Rectosigmoid colon
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H72 F W RIS Rectosigmoid colon
H73 M W RIS Rectosigmoid colon
HP45 F W RIS Down Syndrome Distal Bowel
HP46 M W RIS Down Syndrome Colon
HP47 F C RIS Down Syndrome Colon
HP48* M C RIS Down Syndrome Rectosigmoid colon
HP49* M C RIS Down Syndrome Rectosigmoid colon
HP50 M C RIS Down Syndrome Colon
HP51 F W RIS Down Syndrome Rectum
HP52A F C RIS Down Syndrome Rectosigmoid colon
HP53A F C RIS Down Syndrome Rectosigmoid colon
HP54A F C RIS Down Syndrome Rectosigmoid colon
HP56A F C RIS Down Syndrome Sigmoid colon
HP55l1' F W RIS Down Syndrome Rectal biopsy
HP59l1' F W RIS Down Syndrome Colon
HP57:)i F C RIS Down Syndrome Rectum
HP58:J> F C RIS Down Syndrome Rectum
HP60 F C RIS Down Syndrome Rectal Biopsy
HP61 F C RIS Down Syndrome Colostomy end
HP62 M W RIS Down Syndrome Rectosigmoid colon
Abbreviations: RIS - rectosigmoidal aqanqlionosis: CIA - colonic aqanqlionosis:
TCA - total colonic aganglionosis; M - male; F - female; B - black; W - white; C -
coloured; U - unknown; *A#$ Different sections obtained from these four patients; H -
frozen tissue samples; HP - formalin-fixed paraffin embedded samples.
Table 2.2. Classification of control patients
ID Sex Race Additional Clinical SECTION OBTAINED
Features
KS2 F C Colon
KS3 M C Colon
KS6 M C Colon
KS8 U U Colon
KS12 F C ARM Colon
KS16 M C ARM Colon
KS22 F C ARM Colon
KS24 M B ARM Colon
KS30 M B MECONIUM PLUG Colon
KS31 F W ARM Colon
KS32 U U Colon
KS35 M W Colon
KS43 M W Colon
KP1 F C Adenocarcinoma Colon
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KP2 F C Adenocarcinoma Colon
KP3 F C Adenocarcinoma Colon
KP4 M C Adenocarcinoma Colon
KP5 F C Adenocarcinoma Colon
KP6 M C Adenocarcinoma Colon
KP7 F W Adenocarcinoma Colon
KP8 F W Adenocarcinoma Colon
KP9 M B Adenocarcinoma Colon
KP10 M W Adenocarcinoma Colon
KP11 F C Adenocarcinoma Colon
KP12 F C Adenocarcinoma Colon
KP13 F C Adenocarcinoma Colon
KP14 F C Adenocarcinoma Colon
KP15 M W Adenocarcinoma Colon
KP16 F W Adenocarcinoma Colon
KP17 M C Adenocarcinoma Colon
KB1 F W Blood
KB2 F W Blood
KB3 F W Blood
KB4 F W Blood
KB5 M C Blood
KB6 M W Blood
KB7 F W Blood
KB8 F C Blood
KB9 F W Blood
KB10 F C Blood
KB11 F W Blood
KB12 F W Blood
KB13 F W Blood
KB14 F W Blood
KB15 F W Blood
KB16 F W Blood
KB17 F W Blood
KB18 F W Blood
KB19 F W Blood
KB20 M W Blood
KB21 F ~ alood
KB22 F ~ alood
KB23 F a ~Iood
KB24 F a Blood
KB25 F ~ ~Iood
KB26 F ~ ~_lood
KB27 F ~ ~_lood
KB28 F ~ ê_lood
KB29 F e ê_lood
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KB30 F ~ alood
KB31 F ~ Blood
KB32 F ~ alood
KB33 F a Blood
KB34 F a Blood
KB35 F a Blood
KB36 F a Blood
KB37 F a ~Iood
KB38 F a Blood
KB39 F a alood
KB40 F a Blood
KB41 F ~ alood
KB42 IF a ~Iood
KB43 F a ~Iood
KB44 F a alood
KB45 F a Blood
KB46 F a Blood
KB47 F a Blood
KB48 M ~ Blood
KB49 M ~ alood
KB50 M ~ alood
KB51 M ~ ~Iood
KB52 F ~ alood
KB53 F ~ alood
KB54 F ~ Blood
KB55 F ~ alood
KB56 F ~ alood
Abbreviations: M-male; F-female; W-white; C-coloured; B-black; ARM - anorectal
malformation; KS - frozen tissue samples; KP - formalin-fixed paraffin embedded
samples; KB - blood samples
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2.2. METHODS
2.2.1. DNA extraction procedures
2.2.1.1. DNA extraction from formalin-fixed paraffin-embedded tissue
DNA was extracted from 20 solid colonic tissue samples fixed in formalin and
embedded in paraffin blocks by a technique adapted from Min et al (1991). Briefly,
10X5 1.1 sections were cut from the paraffin blocks and placed into a 1.5 ml
microcentrifuge tube. Xylene (800 1.11) was added to the paraffin sections in the tubes
and was vortexed until the paraffin was dissolved. After the solution was left for 10
min at room temperature, 400 1.11 of EtOH (99%-) was added to the solution, vortexed
and centrifuged for 5 min at 14 000 rpm. The supernatant was removed and the
pellet re-suspended in 800 1.11 EtOH (99%-). The solution was again vortexed and
centrifuged at 14 000 rpm for 5 min. Afterwards, the supernatant was removed and
the pellet air-dried. The dry pellet was resuspended in 800 1.11 of extraction buffer and
incubated overnight at 37°C. The extraction buffer was adapted from that published
by Albert and Fenyo (1990) as follows: 10 mM Tris (pH 8.3), 1mM EDTA, 0.5% Triton
X-100, 0.001% SOS (w/v), 500 I.Ig/ml Proteinase K. The enzyme was inactivated at
94°C for 15 min and the tube sample quenched on ice. The DNA was stored at 4°C.
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2.2.1.2. DNA extraction from solid tissue - method 1
DNA was extracted from 11 frozen colonic solid samples by a modification of the
procedure by Blin and Stafford (1976). Frozen solid tissue samples were thawed at
room temperature. 10-20 mg of tissue was mixed with liquid nitrogen in a porcelain
dish and crushed to a powder. Ice cold, 1 ml phosphate buffered saline (PBS) was
added to the crushed powder and the suspension was placed in a 50 ml
polypropylene Falcon tube and left on ice. The dish was washed with 1 ml of PBS
and added to the solution in the Falcon tube. Recovery of the cells was performed by
centrifugation at 1500 rpm for 10 min at 4°C. The supernatant was removed and the
pellet resuspended in 10Xvolume of ice-cold PBS, followed by centrifugation at 1500
rpm for 10 min. Following removal of the supernatant, the cells were resuspended in
1 ml 1xTE (pH 8.0). Extraction buffer (10 ml)(10 mM Tris (pH 8.0), 0.1 M EDTA (pH
8.0) and 20 IJg/ml pancreatic RNAse, 0.5% SDS) was added to the cell mix and the
solution incubated for 1 hour at 37°C. After incubation, 150 !-IIof proteinase K (100
IJg/ml) was added and the solution was incubated overnight at 55°C.
Following overnight incubation, the solution was cooled to room temperature and an
equal volume of ice-cold phenol-chloroform was added to the solution. The two
phases were gently mixed for 10 min. After centrifugation, the phases were
separated by centrifugation at 1500 rpm for 10 min and the viscous aqueous phase
was transferred to a clean Falcon tube. Two additional phenol-chloroform steps were
performed. After the third extraction with phenol-chloroform, the aqueous phase was
transferred to a clean Falcon tube and 1/10 of the volume of a 5 M NaCI04 and 2
times the volume of ice-cold EtOH (99%-) was added and the solution centrifuged for
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30 min at 40 000 rpm. Following a 70% EtOH wash, the supernatant was removed
and the DNA left to air dry. The DNA was dissolved in 500 !-IIof sterile distilled H20
(ddH20) and left overnight at room temperature to dissolve. This DNA was
transferred to a 1.5 ml microcentrifuge tube and stored at 4°C.
2.2.1.3. DNA extraction from solid tissue - method 2
DNA was extracted from 44 solid colonic tissue samples (frozen tissue) with a
commercially available extraction kit (GenomicPrep™Cells and Tissue DNA Isolation
Kit - Pharmacia Biotech). Briefly, a 1.5 ml tube containing 600 ,",I of cell lysis
solution was kept on ice until the solution turned cloudy. The frozen tissue (10-20
mg) was added to the solution, removed from the ice and homogenised by using a
microfuge tube pestle. Thereafter, 6 !-IIof proteinase K (10 mg/ml stock) was added
to the solution and incubated overnight at 55°C.
Following overnight incubation, 3 ,",Iof Rnase A solution was added to the solution
and mixed by inverting the tube 25 times, followed by incubation at 37°C for 60 min.
After incubation, the solution was cooled to room temperature and 200 ,",Iof protein
precipitation solution was added to the Rnase treated solution. The solution was
vortexed vigorously for 20 min followed by centrifugation at 13 000 rpm for 3 min.
The supernatant was transferred to a fresh 1.5 ml tube containing 600 ,",Iof 100%
isopropanol and gently mixed until the DNA threads were visible. The solution was
vortexed at 13 000 rpm for 1 min, the supernatant removed and the pellet was
washed with 70% EtOH followed by centrifugation at 13 000 rpm for 1 min. The
supernatant was removed and the pellet left on the bench to air-dry. DNA hydration
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solution (100 IJl) was added to the dry pellet and left overnight at room temperature
to rehydrate. The DNA was stored at 4°C. All the components shown in boldface type
were provided as part of the kit.
2.2.1.4. DNA extraction from whole blood
DNA was extracted from 25 whole blood samples by a modification of the technique
of Miller ef al (1988). Cold lysis buffer (40 ml) (0.155 M NH4Cb, 0.01 M KHC03,
0.0001 M EDTA - pH 7.4) was added to each whole blood sample in a 50 ml
polypropylene Falcon tube. The solution was kept on ice until the red blood cells had
undergone lysis and the cell suspension was then centrifuged at 1500 rpm for 10
min. After the supernatant was removed, the pellet was washed twice with 5 ml cold
PBS. The intact pellet was resuspended in 3 ml nucleic lysis buffer (0.01 M Tris-HCI,
0.4 M NaCI, 0.002 M EDTA - pH 8.2), 0.3 ml 10% SDS and 0.5 ml proteinase K, and
incubated overnight in a water bath at 55°C.
Following overnight incubation, 1 ml of saturated 6 M NaCI was added and the
solution shaken vigorously for 1 min, followed by centrifugation at 3000 rpm for 15
min. The supernatant containing the DNA was transferred to a clean Falcon tube.
Three times the volume ice-cold EtOH (99%-) was added and the solution was left at
room temperature for 30 min. The precipitated DNA was transferred to a fresh 1.5 ml
tube and was washed twice with 1 ml of 70% ice-cold EtOH to remove any excess
salt. After centrifugation at 3 000 rpm for 15 min, the excess EtOH was carefully
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removed and the DNA was left to air dry at room temperature. The DNA pellet was
dissolved in 500 IJlddH20 overnight at room temperature and the DNA stored at 4°C.
2.2.1.5. DNA purification and concentration of paraffin-embedded DNA samples
Ethanol precipitation was performed on DNA from paraffin-embedded samples that
did not yield a PCR product after a second round of PCR amplification. A 400 IJl
volume of DNA was mixed with 1/10 the volume of sodium acetate (4 M). Ice-cold 2
times the volume EtOH (99%-) was added and the solution left for 20 min at -BOoC.
The solution was centrifuged for 1 hour at 4°C (13 000 rpm). Afterwards, the
supernatant was removed and the pellet washed with 70% EtOH. The suspension
was centrifuged for 5 min at 30 000 rpm. The supernatant was discarded, the DNA
pellet left to air dry and the DNA pellet subsequently dissolved in 100 IJl of ddH20
(SABAX).
2.2.2. Polymerase Chain Reaction (PCR)
2.2.2.1. Oligonucleotide Primers
The PCR primers used in this study are listed in Tables 2.3., 2.4. and 2.5.
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Table 2.3. Oligonucleotide primers used for DNA amplification of the RET proto-
oncogene (primers previously described by Ceccherini et a/1994)
EXON PRIMERS SEQUENCE
5' 3'
1 R1A(F) GGG CGG CCA GAC TGA GCG C
R1B(R) CTT CGC CCT GGC CCT GCG G
2 R2A(F) AGT GGC ATT GGG CCT CTA C
R2A(R) TGC GGA CAC TGA GCT TCT C
R2B(F) GAA GCC ATA TTC TCA CCA TC
R2B(R) TCT CCC AGG AGC TAT GGT CC
3 R3A(F) GCT CCT GCC TCC TCC CAT TCC
R3B(R) CAG AGC AAG ACC AGC AGT AG
4 R4A(F) CGA GGA AAG CGG CTG GCC CG
R4B(R) ACC GAG AAA CGA ACT GTG GCC G
5 R5A(F) CCT AAG GTC TCT GGT TTT GG
R5B(R) AAG AGC GAG CAC CTC ATT TC
6 R6A(F) CAT GAG GAA GCA GCC AGA GC
R6B(R) AGT GTC ACC TGC CTC CCT GTG
7 R7A(F) TCT CTA CCC TCA GGC CAT
R7B(R) ACC CTC CCT CCC TGG AGC
8 R8A(F) GGC CCA GGC CAG CCC CCT GT
R8B(R) GCC ATC GCC CCT GCA GGC CT
9 R9A(F) GGAGGTGGTGGGGGCGTGTG
R9B(R) GCT GAA GTG CCT GTG GGA TC
10 R10A(F) GGG GCA GCA TTG TTG GGG GA
R10B(R) GTT GGG ACC TCA GAT GTG C
11 R11A(F) TGA GGC AGA GCA TAC GCA GC
R11B(R) GGAGTCCAGCGAGGGCCGGC
12 R12A(F) GCC TTC TIC CTC CCC TGT CAT C
R12B(R) GAG ACT CCC CCA GGG GCA CTG TG
13 R13A(F) AAC TTG GGC AAG GCG ATG CAG
R13B(R) AGA ACA GGG CTG TAT GGA GC
14 R14A(F) CTG GAA GAC CCA AGC TGC CT
R14B(R) GCT GGC TGG GTG CAG AGC C
15 R15A(F) GAC CGC TGC TGC CTG GCC ATG
R15B(R) GCT TC CAA GGA CTG CCT GC
16 R16A(F) AGG GAT AGG GCC TGG GCT TC
R16B(R) TAA CCT CCA CCC CAA GAG AG
17 R17A(F) GGA GGG CTC TGT GAG GGC AG
R17B(R) TCC CCT CCC TTC CCA AGT G
18 R18A(F) GGC TGT CCT TCT GAG ACC TG
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R18B(R) TAC TGC CCT GGG GTG AGG C
19 R19A(F) TAG TTG TGG CAC ATG GCT TG
R19B(R) GAG AGG AAG GAT AGT GCA G
20 R20A(F) GGT TIG AAC ATC AM GGG AG
R20B(R) CCA ATG TGA CGT TCA CAA AG
21 R21A(F) GAG CCT GTG TGA AAG GCC C
R21B(R) CTT GGC CTC ACA AM TGC CAC. .
Abbreviations: F - forward pnmer, R - reverse pnmer
Table 2.4. Oligonucleotide primers used for DNA amplification of the endothe/in-B
receptor (EDNRB) gene (primers previously described by Tanaka et a/1998)
EXON PRIMERS SEQUENCE
5' 3'
1 EB1A(F) TTG TCT CTA GGC TCT GAA AC
EB1B(R) TTA GTG GGT GGC GTC ATI AT
EB1C(F) TCC GCT TIT GCA AAC CGC AG
EB1D(R) GGA CAC AAC CGT GTT GAT G
EB1E(F) ATC GAG ATC AAG GAG ACT TTC
EB1F(R) CCC TTT ACC TIG TAG ACA TIG
2 EB2A(F) TCA ATG CAG CTG CTG GCA G
EB2B(R) AAG CTT CTA CCT GTC AATACT C
3 EB3A(F) TAT CTI CAG ATA TCG AGC TG
EB3B(R) GAA ATT TAC CTG CAT GAA AGC
4 EB4A(F) ATC CCT ATA GTT TTA CAA GAC AGC
EB4B(R) ATT TIC TIA CCT GCT TTA GGT G
5 EB5A(F) TTT ATT TCA GAG ACG GGA AG
EB5B(R) CCT TTC TTA CCT CAA AAG TTC
6 EB6A(F) TTT GTI GCA GCT TIC TGT TG
EB6B(R) AGT CTC TI A CCT TAA AGC AG
7 EB7A(F) TTG TAC AGT CAT GCT TAT GC
EB7B(R) TGT TTI AAT GAC TTC GGT CC. .
Abbreviations: F - forward pnmer, R - reverse primer
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Table 2.5. Oligonucleotide primers used for DNA amplification of the endothe/in-3
gene (EDN3) (primers previously described by Bidaud et a/1997)
EXON PRIMER SEQUENCE
5' 3'
1 E3-1A(F) CGC TCT GAA AGT TTA TGA CCG
E3-1B(R) CCG CCC TGG GTC CTT TTG TG
2 E3-2A(F) CCC TCC TCA GGT GTT TGG
E3-2B(R) TCG GCC GCCTGCTCCTGC
E3-2C(F) TGG CGA GGA GAC TGT GGC
E3-2D(R) GAA TGA GCA GAT GTG GGC G
3 E3-3A(F) GCT CAC CTA ACA TTA CC
E3-3B(R) CCG AGG GTT GAT GCA TAT
4 E3-4A(F) GGT GGG GAA GAG GAA GTC
E3-4B(R) CCC GAA GGA ATG ACA CTG C
5 E3-5A(F) TCA CAG AAC TAC AGA GCT AC
E3-5B(R) ACT GTG TGT GAG CAA TGA C
Abbreviations: F - forward pnmer, R - reverse pnmer
2.2.2.2. DNA amplification
2.2.2.2.1. General PCR
The DNA samples were amplified on a Hybaid Omnigene Thermal Cycler (Hybaid,
Teddington, Middlesex, UK). PCR amplification of the various individual exons were
performed in 25 !-II reactions, overlaid with light mineral oil (Sigma). Each reaction
consisted of 0.2 pmol/pl of each primer, 0.5 U Taq polimerase (Boehringer
Mannheim) enzyme, 0.2 mM of each dNTP (dGTP, dCTP, dATP, dTTP) 5 !-IIbuffer
with MgCI2 (Boehringer Mannheim) and 10 !-IICresol Red (0.0382 g Cresol Red and
60g sucrose up to a final volume of 100 mi). Modifications for exons 1 and 4 of RET
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proto-oncogene included the addition of 10% DMSO and 1% Formamide,
respectively, to the PCR reaction.
2.2.2.2.2. RET proto-oncogene
The optimal PCR conditions for exons of the RET proto-oncogene were as follows:
an initial denaturation step at 95°C for 5 min, followed by 35 cycles of denaturation at
94°C for 1 min and annealing as specified for each exon in Table 2.6. for 2 min. This
was followed by an extension step at 72°C for 10 min and a final step at 30°C for 1
min.
Table 2.6. Annealing temperatures for the RET proto-oncogene
EXON ANNEALING
TEMPERATURE (OC)
2A 66
3 67
4 64
5 66
6 68
8 70
9 67
12 69
13 67
14 59
15 71
16 69
17 63
The PCR conditions for the remaining exons were as follows: an initial denaturation
step for 2 min at 95°C, followed by 10 cycles of denaturation at 95°C for 30 seconds,
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annealing as specified for each exon in Table 2.7. (column 1) for 45 seconds, and an
extension at 72°C for 30 seconds. This was followed by 30 cycles of the same
conditions but with an annealing temperature as specified in Table 2.7. (column 2),
followed by an extension step at 72°C for 5 min and a final step of 1 min at 30°C. The
exons with only one annealing temperature (column 3) specified, were amplified for
35 cycles.
Table 2.7. Annealing temperatures for the RET proto-oncogene
EXON ANNEALING TEMPERATURE
(oC)
column 1 column 2 column 3
1 60
28 60 58
7 63 60
10 65 63
11 66 63
18 60
19 60
20 59 56
21 67 64
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2.2.2.2.3. Endothelin-B receptor gene (EDNRB)
The optimal PCR conditions were as follows: an initial denaturation step at 95°C for 5
min, followed by 35 cycles of denaturation at 94°C for 1 min and annealing at 60°C
for 2 min. This was followed by an extension step at 72°C for 10 min and a final step
at 30°C for 1 min. All seven exons were amplified by the same procedure.
2.2.2.2.4. Endothelin-3 gene (EDN3)
The optimal PCR conditions were as follows: an initial denaturation step at 95°C for 5
min, followed by 35 cycles of denaturation at 94°C for 1 min and annealing as listed
in Table 2.8. This was followed by an extension step at 72°C for 10 min and a final
step at 30°C for 1 min.
Table 2.8. Annealing temperatures for the endothelin-3 gene (EDN3)
EXON ANNEALING TEMPERATURE(Oe)
1 62
2A 67
28 67
3 60
4 60
5 66
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2.2.3. Agarose Gel Electrophoresis
Successful amplification of peR products was tested on a horizontal agarose gel
(2%). The peR product (5 ~I) was mixed with an equal volume of ficoll-orange G
loading buffer (consisting of 0.1 g Orange G, 20 g Ficoll and 0.29 g EDTA up to a
final volume of 100 ml (pH 7.0)) and loaded on the gel. The products were resolved
at 150 V for 30 min in 1xTBE buffer solution and 0.01% (v/v) of ethidium bromide for
staining purposes. The products were visualised by ultraviolet light transillumination
assisted by a UVP Image Store 5000 Ultra-Violet transilluminator system and
photographedwith the Sony Video Graphic Printer (UP 860 LE) system.
2.2.4. Heteroduplex single-strand conformation polymorphism
(HEX-SSCP) analysis
HEx-ssep analysis of the peR fragments of the RET proto-oncogene, endofhelin-B
receptor and endofhelin-3 gene, was performed on a 30 cm vertical gel apparatus.
Different gel compositions were used to increase the sensitivity of mutation detection,
including a 12% polyacrylamide (PAA) (39.6 g acrylamide and 0.4 g bisacrylamide up
to a final volume of 100 ml) gel supplemented with 7.5% urea (consisting of 4.5g
Urea, 18 ml 5XTBE, 24 ml dH20, 18 ml PAA (1%e of a 40% stock), 600 ~I APS
(10%) and 60 ~I TEMED), and a 10% PAA gel supplemented with 5% glycerol
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(consisting of 3 ml glycerol, 6 ml 5XTBE, 36 ml dH20, 15 ml PAA, 800 jJl APS (10%)
and 80 jJl TEMED) (Kotze et a/1995).
A 0.75 mm gel was cast and once polymerised, prepared for loading of the PCR
products. Gels were placed in a Hoefer electrophoresis tank filled with fresh 0.5 X
TBE buffer. The upper buffer chamber was filled with 1.5 X TBE buffer for an urea gel
and 0.5 X TBE for a glycerol gel.
The PCR products were heat denatured for 5 min at 95°e and then kept on ice.
Approximately 7 jJl of the denatured peR product was loaded on the gel. The PCR
products of exon 18 (failed to amplify in the presence of Cresol Red) were mixed with
an equal volume of loading buffer (consisting of 22.7 ml Formamide (De-ionised),
0.168 g EDTA (disodiumsalt), 0.0125 g Xylene Cyanol and 0.0125 g Bromophenol
blue up to a final volume of 25 ml) before denaturing at 95°C. Approximately 18 jJl of
this product was loaded on the gel. Electrophoresis was as follows: for 12% urea gels
electrophoresis was performed at 300 V at 4°C (cold room) for 20 hours and for 10%
glycerol gels at 250 V at room temperature for 18 hours.
SSCP analysis was also performed on a 9 cm vertical gel (Hoefer system) and
similar procedures were used for setting up and preparing the peR products as for
HEX-SSCP analysis. A gel consisting of 20% PAA (consisting of 5 ml PAA (1%e of a
40% stock), 1 ml 5XTBE, 4 ml dH20, 80 jJl APS (10%) and 25 jJl TEMED) was used
for this system and electrophoresis of the PCR products was performed at 150 V for
20 hours at 4°C.
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Following electrophoresis, the gel was dismantled and stained in 0.01% (v/v)
ethidium bromide for 10 min and destained in ddH20 for 3 min. The DNA fragments
were visualised by ultraviolet light transillumination assisted by the UVP Image Store
5000 Ultra-Violet transilluminator system and photographed with the Sony Video
Graphic Printer (UP 860 LE) system.
2.2.5. AUTOMATED SEQUENCING
Automated DNA sequencing was performed on PCR products demonstrating HEX-
SSCP mobility shifts. The PCR products were pre-treated enzymatically by adding
0.5 IJl exonuclease I (1.2 U/IJl) (removes residual single strand primers and
extraneous DNA products) and 0.5 IJl Shrimp Alkaline Phosphatase (6 U/IJl)
(removes remaining dNTP's) to 5 ui of PCR product and incubating the reaction for
15 min at 37°C, followed by incubation at 80°C for 15 min to inactivate the enzymes.
The enzymatically treated product was added to a reaction mix which consisted of 2
IJl termination ready reaction mix, 3 IJl 5Xdilution buffer, 2.5 pmol primer and 7.5 IJl
ddH20 (Applied Biosystems ™ automated sequencing kit). This was followed by cycle
sequencing on a 2 400 Perkin Elmer PCR cycler. The cycle program was as follows:
an initial denaturation step at 94°C for 2 min, followed by 30 cycles of denaturation at
94°C for 20 sec, annealing at 59°C for 20 sec and an extension at 60°C for 30 sec.
This was followed by an extension step at 72°C for 5 min and a final step at 25°C for
10 min.
After cycle sequencing, the products were cleaned by spun-column chromatography
using centri-sep columns (Applied Biosystems). After spun-column chromatography,
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20 jJl MgCb (20 jJg/ml) and 55 jJl 95% EtOH were added to the products. The solution
was left on the bench for 10 - 15 min, followed by centrifugation for 15 - 20 min at
13 000 rpm. The supernatant was removed and the pellet left to air-dry. Template
suppressant reagent was added to the dry pellet and the products were loaded on an
ABI 310 automated sequencer. Following electrophoresis, analysis of
electropherograms were performed by using sequencing analysis software supplied
by Applied Biosystems.
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CHAPTER 3
RESULTS
Presented in the form of a full-length manuscript in preparation for future publication
in a scientific journal.
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Mutation analysis of the RET proto-oncogene (REn, Endothelin-B receptor
(EDNRB) gene and Endothelin-3 (EDN3) gene loci in sporadic Hirschsprung's
disease in the South African population.
Abstract
Hirschsprung's disease (HSCR) is a common cause of intestinal obstruction in
neonates with an incidence of 1 in 5000 live births. The disease occurs due to the
absence of parasympathetic neuronal ganglia in the hindgut, resulting in irregular or
sustained contraction of the affected segment. DNA samples of 53 unrelated subjects
with sporadic HSCR were screened for mutations in the RET proto-oncogene, a
major susceptibility gene for HSCR, as well as the endothelin-B receptor (EDNRB)
and the endothelin-3 genes (EDN3). Five novel and one previously described
mutation were identified in the RET proto-oncogene. Mobility shift aberrations
identified in the EDNRB gene represented polymorphisms. No sequence variants
were identified in the EDN3 gene. Potential disease-related mutations were identified
in the RET proto-oncogene in 19% of individuals and more males (24% representing
9 of 37 males) were affected than females (6% representing 1 of 16 females). This
study demonstrated that all the potential disease-related mutations identified in South
African patients with sporadic HSCR occur in the RET gene. A mutation in RET was
identified in only 2 of 14 patients (14%) presenting with HSCR and Down's syndrome
compared to 6 mutations identified in 8 of 39 patients (20.5%) with only HSCR.
Stellenbosch University http://scholar.sun.ac.za
48
Introduction
Hirschsprung's disease (HSCR), or aganglionic megacolon, occurs due to the
absence of parasympathetic neuronal ganglia in the hindgut and results in a
malfunction of the affected segment. The condition therefore presents as a common
cause of intestinal obstruction in neonates, with an incidence of 1 in 5000 (0.02%)
live births and an overall risk to siblings of 4% (Passarge 1967, Angrist et a/1993,
Lyonnet et al 1993). Aganglionosis can involve the rectosigmoid area (75%),
transverse colon (17%) or total colon with a short segment of the terminal ileum (8%).
Clinical features of HSCR vary from colonic obstruction to colonic dysfunction and
the presence of one or more of the following symptoms: severe constipation,
megacolon, secondary electrolyte disturbances and sepsis due to enterocolitis.
Males are more likely to be affected than females (3.5-7.8 fold higher risk) and as the
aganglionic segment becomes more extensive, the risk to siblings increases and the
sex ratio decreases (Badner et al 1990, Puri 1997). A higher risk of disease
occurrence has been reported in siblings of patients demonstrating an earlier age of
onset.
The suspected basis of HSCR was believed to be a sex-modified multifactorial trait
because males are more likely to be affected than females (Passarge 1967).
Thereafter, inheritance was suggested to be multifactorial with the involvement of
multiple genes and environmental factors in the development of the clinical
phenotype. However, the occurrence of the disease in individuals displaying
chromosomal abnormalities and sometimes multiple chromosome aberrations,
suggested genetic heterogeneity (Badner et al 1990). Chromosomal abnormalities
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such as Down's syndrome are often (2% - 15%) associated with HSCR (Puri 1993,
Polly and Coran 1993). The relatively constant association of Down's syndrome with
HSCR disease suggests the involvement of another gene on chromosome 21 in the
pathogenesis of the disease (Passarge 1967). Studies performed more recently
using identity-by-descent (lBO) and linkage disequilibrium analysis in a Mennonite
kindred revealed preliminary evidence of a genetic modifier for HSCR on
chromosome 21q22-q23 (Puffenberger et a/1994b).
The first gene implicated in HSCR was the RET (REarranged during transfection)
proto-oncogene. This was demonstrated by the detection of an interstitial deletion of
10q occurring in a patient with long segment HSCR, as well as extensive segregation
analysis of this area in large HSCR families demonstrating dominant inheritance
(Lyonnet et al 1993, Luo et al 1993, Angrist et a/ 1995). RET involvement was
substantiated by the identification of mutations associated with both familial and
sporadic cases in 25% of all HSCR cases (Romeo et a/1994, Edery et a/1994a, Luo
et a/1994, Attie et a/1995a, Angrist et a/1995, Seri et a/1997). The frequency of
RET gene mutations is higher in familial cases (28.4%) than in the more common
sporadic cases (17.6%). In familial cases, 35.6% of RET mutations are associated
with long segment disease and 29.6% with short segment disease. RET mutations in
sporadic HSCR occurs in 42.2% of patients with long segment disease and in 7.9%
of patients with short segment disease (Puri 1997). In both familial and sporadic
cases of HSCR, RET mutations are not restricted to a particular area of the gene.
Involvement of the endothelin-B receptor gene (EDNRB) and its ligand the
endothelin-3 gene (EDN3) in HSCRwas first recognised when targeted disruptions of
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these genes in mice resulted in a similar phenotype in both cases, that of aganglionic
megacolon and spotted coat colour (Baynash et a/1994). Puffenberger et al (1994b)
localised EDNRB, the second susceptibility gene for HSCR, to chromosome 13q22
by identity-by-descent (lBO) analysis followed by linkage disequilibrium analysis of an
inbred Mennonite kindred. A missense mutation ryv276C) identified in these studies
demonstrated incomplete penetrance, as some unaffected individuals were
homozygous for the same mutation, implicating the involvement of other
susceptibility genes in HSCR pathogenesis. The EDN3 gene was localised to
chromosome 20q13.2-13.3 by in situ hybridisation analysis (Gopal Rao et al 1991,
Arinami et a/1991). Recent studies indicated that heterozygous mutations resulted in
isolated HSCR or central hypoventilation syndrome (CCHS) (Bolk et a/1996a).
In order to determine the molecular basis of HSCR in the South African population,
we performed polymerase chain reaction (PCR) amplification and heteroduplex
single-strand conformation polymorphism (HEX-SSCP) analysis of RET, EDNRB and
EDN3 loci in samples from 53 unrelated patients with sporadic HSCR.
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Materials and Methods
Subjects
Colonic tissue samples were obtained from 53 (12 paraffin embedded and 41 frozen
tissue samples) apparently unrelated HSCR patients and 30 control subjects (17
paraffin embedded and 13 frozen colonic tissue samples), including six patients with
anorectal malformations. DNA samples, extracted from whole blood, of an additional
56 subjects (27 blacks, 12 coloureds and 17 whites) were included as controls.
Inclusion of HSCR patients were based on histopathological evaluation and
confirmation of absence of ganglia in the biopsies. Fourteen of the 53 HSCR patients
were also clinically diagnosed with Down's syndrome and different sections of the
colon, with and without ganglion cells, were obtained for 4 of these patients. HSCR
occurred sporadically in all of the patients. Total colonic aganglionosis was observed
in seven of these patients and the remaining patients all had aganglionosis restricted
to the rectosigmoid area.
The study population were from different ethnic groups of South Africa, including 58
coloureds (21 HSCR patients - 54%; 8 HSCRlDown's syndrome patients - 57%; 29
controls - 34%), 39 blacks (9 HSCR patients - 23%; 30 controls - 35%;) and 39
whites (8 HSCR patients - 21%; 6 HSCR/Down's syndrome patients - 43%; 25
controls - 29%). The ethnic origin of 1 HSCR patient (1.9%) and 2 controls (2%)
were unknown. In this study "white" refers to an individual of European descent,
mainly Dutch, French, German and British stock; "coloured" refers to an individual of
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mixed ancestry, including San, Khoi, African Negro, Madagascar, Javanese and
European origin; "black" refers to South Africans of central African descent.
Methods
DNA extraction was performed on the colonic tissue samples and whole blood using
standard techniques. Polymerase chain reaction (PCR) amplification of the 21 exons
of RET, 7 exons of EDNRB and 5 exons of EDN3 was performed using intronic
primers (Ceccherini ef al 1994, Bidaud ef al 1997, Tanaka ef al 1998). The PCR
products were subjected to heteroduplex single-strand conformation polymorphism
(HEX-SSCP) analysis (Kotze ef al 1995). Briefly, seven !-IIof heat denatured PCR
product in Cresol Red loading buffer was resolved on a 12% polyacrylamide (PAA)
gel supplemented with 7.5% urea (consisting of 4.5 g urea, 18 ml 5XTBE, 24 ml
dH20, 18 ml PAA (1%C of a 40% stock), 600 !-IIAPS (10%) and 60 !-IITEMED) at 4°C
(350 V) for 18 hr in a Hoefer vertical gel-electrophoresis system. The DNA fragments
were also resolved in a 10% PAA gel supplemented with 5% glycerol (consisting of 3
ml glycerol, 6 ml 5XTBE, 36 ml dH20, 15 ml PAA (1%C of a 40% stock), 800 !-IIAPS
(10%) and 80 !-II TEMED) at room temperature (300 V). Following adequate
electrophoresis time for separation of PCR fragments, the gel was dismantled and
stained in 0.01% (v/v) ethidium bromide for 10 minutes and destained in double
distilled H20 for 3 minutes. The DNA fragments were visualised by ultraviolet light
transillumination and photographed. Automated DNA sequencing was performed on
PCR products demonstrating mobility or conformational variants in the PAA gels,
using a custom-made kit from Applied Biosystems TM. The products were loaded on
an ABI 310 automated sequencer and following electrophoresis, analysis of the
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electropherograms was performed by using sequencing analysis software supplied
by Applied Biosystems.
Statistical analysis
Allele frequencies were determined by allele counting. Testing for significance of
heterogeneity in mutation frequencies among patient and control groups was based
on the chi-square <X2) and Fisher's exact tests. A p value smaller than 0.05 was
regarded as statistically significant.
RESULTS
Mutation analysis of the RET proto-oncogene revealed 6 potential disease-related
mutations in 10 HSCR patients (Table 3.1.). Nine polymorphisms, of which five were
previously described (Ceccherini et a/1994, Edery et a/1994b, Romeo et a/1994)
and four novel, were also detected (Table 3.2.). HEX-SSCP analysis showed no
aberrant banding pattern in exons 1,4,5,8,9, 10, 12 and 16 of the RET gene, in any
of the HSCR patients. Missense mutations and splice variants were identified in
exons 3, 7, 13 and 17, and introns 10 and 19, respectively. These mutations were
absent in the control individuals. Although IVS16-38de1G was detected only in
patients with HSCR and not in control individuals, this apparently rare variant are
unlikely to contribute to the disease phenotype, based on the location in the RET
gene.
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Table 3.1. Potential disease-causing mutations identified in the RET proto-
oncogene
PATIENT EXONI MUTATION NUCLEOTIDE EFFECT ON GENDER! EXTENT OF
NR INTRON CHANGE CODING ETHNIC AGANGLIONOSIS
SEQUENCE GROUP
7 3 V202M GTG-+ ATG Missense M/C RIS
46** 3 V202M GTG-+ATG Missense M/C RIS
18 7 E480K GAA-+AAA Missense M/C RIS
29 7 E480K GAA-+AAA Missense M/C RIS
39 7 E480K GAA-+AAA Missense M/C RIS
21 10 IVS10-2AlG Splice acceptor M/C RIS
11 13 D771N GAC-+AAC Missense M/C TCA
28 13 D771N GAC-+AAC Missense MIW TCA
44** 17 P973LII' CCA-+CTA Missense F/C RIS
4 19 IVS19-9CIT Splice acceptor MIW RIS
#Flrst reported by Yin et a/1994
**HSCRlDown's syndrome patients
Abbreviations: M - male. F - female. W - white. C - coloured. TCA - total colonic aganglionosis.
RIS - rectosigmoidal aganglionosis; IVS - intervening sequences
Table 3.2. Polymorphisms identified in the RET proto-oncogene
EXONI CODON NUCLEOTIDE ALLELE FREQUENCY
INTRON CHANGE B BC W WC C CC
(n=9) (n=30) (n=14) (n=25) (n=29) (n=291
2 A45 GCG--'GCA G:0.95 0.94 0.47 0.42 0.48 0.69
A:0.05 0.06 0.53 0.58 0.52 0.31
6 IVS6+56deIG G:1.0 1.0 0.97 1.0 0.86 0.90
deIG:O.O 0.0 0.03 0.0 0.14 0.10
7 A432 GCG--'GCA G:1.0 1.0 1.0 0.94 0.83 0.87
A:O.O 0.0 0.0 0.06 0.17 0.13
13 L769 Cn--'CTG T:0.78 1.0 0.81 0.70 0.64 0.70
G:0.22 0.0 0.19 0.30 0.36 0.30
13 IVS 13-29CIT C:0.95 0.98 1.0 1.0 0.97 1.0
T:0.05 0.02 0.0 0.0 0.03 0.0
15 S904 TCC+TCG C:0.50 0.75 0.71 0.94 0.59 0.58
G:0.50 0.25# 0.29 0.06* 0.41 0.42
16 IVS 16-38de1G G:1.0 1.0 1.0 1.0 0.96 1.0
deIG:O.O 0.0 0.0 0.0 0.04 0.0
18 R982 CGC_'CGT C:1.0 0.91 0.90 0.89 0.94 0.97
T:O.O 0.09 0.10 0.11 0.06 0.03
21 X1159 TAA--'TGA A:1.0 1.0 1.0 1.0 1.0 0.98
G:O.O 0.0 0.0 0.0 0.0 0.02
II, -black patients versus black control group. X 4.06. p<O.05
"white patients versus white control group: X2 = 7.34; p<O.01
Abbreviations: B- black patients. Be - black control group. W - white patients. we - white control group. e -
coloured patients, CC - coloured control group
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All the patients were heterozygous for the respective mutations identified. The
missense mutations (4/6) are scattered throughout the extracellular and intracellular
domains of the RET proto-oncogene. Both mutations V202M and E480K, detected in
the extracellular domain of the RET proto-oncogene, were observed in men with
aganglionosis restricted to the rectosigmoidal area. A mutation altering the splice site
in intron 10 (IVS10-2A1G) was identified in a male with rectosigmoid aganglionosis.
The mutations in exons 13 (D771 N) and 17 (P973L) (Yin et al 1994) are located in
the intracellular domain. The mutation in exon 13 was identified in two patients, both
with total colonic aganglionosis. A rare variant was identified in intron 16 (IVS16-
38delG) in the same individual with the missense mutation in exon 17 (P973L). Only
one patient with rectosigmoid aganglionosis presented with the mutation identified in
intron 19 (IVS19-9CIT).
Codon numbers were used for designation of the polymorphisms, because
discrepancies were observed between the intronic sequences published by
Ceccherini et al (1994) and Munnes et al (1999) (Blast #AJ243297). Statistically
significant differences in allele frequencies of the polymorphism identified in exon 15
was observed between the patient and control groups from the black and white
populations.
HEX-SSCP analysis of the EDNRB and EDN3 genes demonstrated less variation.
No sequence changes were observed in the EDN3 gene, while all the variants
detected in the EDNRB gene appears to be neutral polymorph isms (Table 3.3). No
statistically significant differences in allele frequencies were observed between
patient and control groups in the different ethnic groups studied.
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Table 3.3. Polymorphisms identified in the EDNRB gene
EXONI CODON NUCLEOTIDE ALLELE FREQUENCY
INTRON CHANGE B BC W WC C CC
(n=9) (n=30) (n=14) (n=25) (n=29) (n=29)
1 A60T GC~ACC G:O.94 1.0 0.95 1.0 0.96 0.98
A:O.06 0.0 0.05 0.0 0.04 0.02
2 8184 TCC-.TCT C:1.0 0.97 0.96 1.0 0.94 1.0
T:O.O 0.03 0.04 0.0 0.06 0.0
2 1187 ATC-'ATT C:O.94 0.95 0.89 0.96 0.90 0.98
T:O.06 0.05 0.11 0.04 0.10 0.02
3 V234 GTC-.GTT C:1.0 0.93 0.98 0.97 1.0 0.82
T:O.O 0.07 0.02 0.03 0.0 0.18
4 L277 CTG-.CTA G:O.46 0.47 0.46 0.45 0.43 0.45
A:0.54 0.53 0.54 0.55 0.57 0.55
3 IV84-6CfT C:0.55 0.54 0.56 0.55 0.57 0.56
T:0.45 0.46 0.44 0.45 0.43 0.44
4 IV84+3NG A:0.69 0.68 0.72 0.70 0.72 0.71
G:0.31 0.32 0.28 0.30 0.28 0.29
Abbreviations: B- black patients, Be - black control group, W - white patients, we - white control group, e -
coloured patients, CC - coloured control group.
Discussion
Mutation analysis of the RET, EDNRB and EDN3 genes in a series of 53 unrelated
sporadic HSCR cases, revealed five novel mutations and one previously described
mutation in the RET proto-oncogene in 10 of 53 (19%) individuals studied. Notably,
all the missense mutations identified in the study population involve amino acids
which have remained evolutionarily conserved in human, mouse and rat. Eight
polymorphisms, of which three were novel and five previously described, were also
detected. Seven polymorphisms were identified in the EDNRB gene whilst no
sequence changes were identified in the EDN3 gene. This finding was not
unexpected since none of the individuals included in the panel of South African
HSCR patients presented with a HSCRlWaardenburg syndrome phenotype,
frequently associated with these genes (Puffenberger et al 1994, Chakraverti et al
1996, Edery et a/1996, Hofstra et a/1996).
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The percentage of individuals presenting with RET mutations in this study (19%) is in
accordance with the findings by Edery et al (1994) and Romeo et al (1994), who
indicated that RET gene mutations account for approximately 25% of HSCR cases.
The majority of mutations (80%) were detected in the coloured population, while only
two of the 10 RET mutations (20%) identified occurred in white patients. No
mutations were identified in the black population. The mutations identified to date in
RET are scattered throughout the gene (figure 3.1) and a similar picture has
emerged in this study.
Two mutations were identified in the extracellular domain of the gene, encompassing
exon 3 (V202M) and exon 7 (E480K). Exons 3 and 7 partly encode the cadherin-like
domain and the cysteine-rich area, respectively. Consensus calcium-binding
sequences, also present in the cadherin-like domain of the RET proto-oncogene,
were shown to mediate calcium binding and calcium-dependent homophilic
interactions with cadherin molecules on other cells (Takeichi 1991, Overduin et al
1995). Mutations in this area may cause RET loss-of-function by a dominant-negative
mechanism (Cosma et al 1998) whereas mutations in the cystein residues mainly
result in tumorigenesis because of the activation of RET function in patients with
MEN 2A and FMTC (Eng et al 1996). Mutations involving the extracellular domain
were shown to inhibit transport of the RET protein to the plasma membrane, causing
a low expression of p170ret at the cell surface.
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Figure 3.1. Schematic representation of genomic organisation of the RET proto-oncogene in relation to three distinct functional
domains of the protein. Mutations identified in the South African population are shown. A) Exons encoding for specific domains of
the RET protein, B) Ethidium bromide stained gel images of PCR-8SCP banding patterns of mutations in 12% polyacrylamide gels
supplemented with 7.5% urea. Arrows indicate abnormal bands; S - signal peptide; Cd - cadherin-like sequence; Cys - cysteine-rich
region; Tm - transmembrane domain; TK1 and TK2 - split tyrosine kinase regions 1 and 2.
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A splice variant (IVS10-2A1G) was identified in intron 10 in an individual with
aganglionosis in the rectosigmoid area. Efficient splicing depends on accurate
cleavage and rejoining, which appears to be determined by the GT and AG
dinucleotides present at the 5' and 3' exon/intron boundaries, respectively. This
splice site mutation, altering the AG dinucleotides at the 3' region of the intron, most
likely disrupts accurate splicing and interferes with the correct processing of the
primary transcript. A sequence variant was also identified in intron 19 (IVS19-9CIT).
The consensus sequence reported by Padgett et al (1986) showed that sequence
changes at position -9 of the 3' splice site, resulting in the substitution of any
nucleotide for a pyrimidine, affected the protein structure in 82% of cases. The splice
variant can therefore result in abolishing or a reduction in the amount of mRNA. RNA
studies might, however, give a more definite answer.
Mutations in exon 13 (D771N) and exon 17 (P973L) involve the intracellular domain,
the most highly conserved area of the gene. Missense mutations in the intracellular
domain may impair tyrosine kinase activity. The mutation in exon 17 (P973L) was
previously described by Yin et al (1994) who speculated that this mutation might
inactivate RET gene function. Subsequent identification of this mutation in a patient
with a family history of HSCR. who was not included in this study, reflects the low
penetrance of the disease. The variant identified in intron 16 (IVS16-38deIG)
occurred in the two HSCR patients with mutation P973L, and therefore these
sequence changes are probably located on the same chromosome. This variant
appears to be a neutral polymorphism that segregates with the mutation, since it was
not detected in 86 (172 chromosomes) control subjects.
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The study included fourteen patients who were clinically diagnosed with both HSCR
and Down's syndrome. A mutation in RETwas identified in only two of these fourteen
patients (14%), compared with 6 mutations identified in 9 of 39 patients with only
HSCR (23%). A gene on chromosome 21q has previously been suggested by
Puffenberger et al (1994b) for individuals with bath HSCR and Down's syndrome.
Petersen et al (1991) previously localised a possible susceptibility gene to
chromosome 21q22.1-22.3.
Different sections of the colon with and without ganglion cells were obtained for four
of the HSCR patients who also presented with Down's syndrome. Discrepancies in
the occurrence of polymorphic variants in exons 6 (IVS6+56delG), 7 (A432) and 15
(S904) of the RET proto-oncogene and exon 2 (S184 and 1187) of the EDNRB gene
were observed in the different tissue samples of these individuals (data not shown).
The significance of this finding is currently under investigation but could indicate the
occurrence of somatic silent mutations in situ in the colon. The role of these
polymorph isms in the etiology of HSCR could be postulated to occur at the
transcriptional level, thereby influencing the amount of RET protein produced and in
turn mediating an altered effect in the enteric neural system.
Although the numbers were small for statistical analysis, a varying trend was
observed upon comparison of the exon 15 polymorphism of the RET gene in both the
coloured and white patients versus the respective control groups. The observed trend
of polymorphic allelic frequency variation in the HSCR and HSCR/ Down's syndrome
patient groups, consisting mainly of colon tissue, and the mainly blood-derived
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coloured and white patients versus the respective control groups. The observed trend
of polymorphic allelic frequency variation in the HSCR and HSCRI Down's syndrome
patient groups, consisting mainly of colon tissue, and the mainly blood-derived
control group, could indicate a higher susceptibility of specific tissues to mutational
change. In light of the role that RET plays in the cellular signalling pathway between
different cells, this finding warrants further investigation as recent evidence indicates
that silent mutations may possibly influence RET transcription and lead to altered
protein levels causing phenotypic changes through interaction with other mutated
genes (Borrego et a/1999, Fitze et a/1999). The likelihood that variant S904 may be
in linkage disequilibrium with other disease-causing mutation(s) in the gene should
also be considered, particularly in the black patient group where no mutations could
be found. The low mutation detection rate in this study is probably a consequence of
the heterogeneous nature of HSCR, but limitations imposed by the HEX-SSCP
screening method (Kotze et a/1995) used may also be a contributing factor.
Although no direct evidence concerning the causative nature of the novel mutations
is provided, either through loss of activity, enhanced activity or altered specificity of
the protein, several lines of evidence support their significance in HSCR. All the
missense mutations have been detected in more than one HSCR patient, while
absent in the control groups. Screening for these four potentially founder-type
mutations, V202M, E480K, 0771 Nand P973L, may facilitate an improved diagnosis
of HSCR in South Africa, particularly in the coloured population where nearly 30% of
sporadic HSCR cases were characterised at the molecular level. This study
represents the first comprehensive genetic study of HSCR in the diverse South
African population.
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CHAPTER4
DISCUSSION, CONCLUSION
and FUTURE PROSPECTS
Stellenbosch University http://scholar.sun.ac.za
63
4.1. DISCUSSION
The identification of interstitial deletions of chromosome 10 in patients with HSCR
implicated the involvement of chromosome 10 in the pathogenesis of the disease.
Subsequently, the gene was localised to chromosome 10q11.2, the RET proto-
oncogene (Martucciello et a/1992, Luo et a/1993). Targeted disruption of the Ednrb
and Edn3 genes in mice, respectively, resulted in aganglionic megacolon and white
coat-spotting (Hosoda et al 1994, Gariepy et al 1996). These findings established
RET, EDNRB and EDN3 as important components in the normal development of the
enteric ganglion neurons and epidermal melanocytes (neural crest-derived cell
lineages) during the early stages of embryogenesis.
Criteria to determine whether a missense mutation contributes to the disease
pathogenesis were constructed by Hofstra et al (1997), occuring as a single entity or
in a combination. These criteria include: 1) a mutation occurring as a de novo
mutation, 2) the segregation of the mutation with the disease within pedigrees, 3)
absense of the mutation in control individuals, 4) a change in the polarity of an amino
acid or its size in the encoded peptide, 5) amino acid substitution in an area which is
evolutionary conserved between species and/or shared between proteins of the
same protein family, 6) effect of the mutation in an animal model or functional in vitro
system, 7) mutation included in previously reported disease-specific mutation
databases. Points 3, 5 and 7 were considered to assess the likelihood that the novel
mutations identified in this study may cause or at least contribute to the HSCR
phenotype.
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Several mutations and polymorphisms were identified in the RET and EDNRB genes
after investigating 53 unrelated sporadic HSCR patients from different ethnic groups
in South Africa. Mutations identified in the RET gene (figure 4.1) may affect different
domains of the RET protein, resulting in altering expression. The RET gene is divided
into an extracellular domain (exons 1-10), a transmembrane domain (exon 11) and
an intracellular domain (exons 12-21). The novel mutations identified in this study will
be discussed in relation to their presumed functions in altering protein expression.
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Figure 4.1. Mutation spectrum of the RET proto-oncogene (from Eng and Mulligan
1997)
Stellenbosch University http://scholar.sun.ac.za
66
4.1.1. RET PROTO-ONCOGENE
4.1.1.1. Extracellular domain
The function of the extracellular domain is to bind signalling molecules (for a review
see Hóppener and Lips 1996). Mutations in the extracellular domain inhibit transport
of the RET protein to the plasma membrane and result in a low expression of RET at
the cell surface (Iwashita et al 1996). Studies performed by Iwashita et al (1996)
suggested that sufficient levels of RET expression on the cell surface are required for
ganglia migration toward the distal part of the colon or for full differentiation. Cosma
et al (1998) illustrated that mutations in the extracellular domain causes RET loss of
function by a dominant-negative mechanism. The extracellular domain includes the
cadherin-like sequence and the cysteine rich region.
4.1.1.1.1. Cad herin-like sequence (exons 2-6)
The novel G to T transition identified in exon 3 (V202M) resulted in the replacement
of a valine for a methionine. This mutation was identified in two males with
aganglionosis restricted to the rectosigmoid area. Two polymorphic variants were
identified in exons 2 and 6. Several functions for this area have been postulated.
RET is expressed as a 150-kDa precursor form and a 170-kDa mature form
(glycoproteins) in the endoplasmic reticulum and the plasma membrane,
respectively. A cadherin-like domain, consisting of 110 amino acids, is present in the
extracellular domain of the RET proto-oncogene. Cadherins mediate calcium binding
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and calcium-dependent homophilic interactions with cadherin molecules on other
cells and in RET these consensus calcium-binding sequences are also present
(Takeichi 1991). Calcium binding is also essential for the correct folding of cadherin
molecules (Overduin et al 1995). A study performed by Asai et al (1995)
demonstrated that a point mutation in the cadherin-like domain resulted in a dramatic
reduction of p170fflt expression at the plasma membrane, but did not affect the
expression of p150fflt. They hypothesised that mutations in the putative calcium
binding site might: 1) interfere with processing of RET in the golgi complex, 2)
interfere with RET transport to the plasma membrane, or 3) full processing and
transport of RET to the plasma membrane occurs, but it cannot be retained at the
plasma membrane in the absence of calcium binding.
Van Weering et al (1998) investigated the role of calcium in p170fflt expression
because of observations that a mutation in the putative calcium-binding domain of
RET leads to aberrant expression of p170fflt. Depletion of extracellular calcium
resulted in down-regulation of p170fflt but did not affect p150fflt expression. It was
shown that piso= is the precursor of p170fflt and that a mutation of the putative
calcium-binding site of RET can also inhibit p150fflt processing (Asai et al 1995).
Mutations identified in the extracellular domain resulted in reduced levels of p170fflt
expression at the plasma membrane and the length of aganglionosis correlates with
the degree of impaired p170fflt expression (Iwashita et al 1996, Carlomagno et al
1996). The extracellular domain of RET is therefore very sensitive to mutations that
alter either RET processing or RET retention at the plasma membrane and these
mutations may cause a defect in proper folding of p150fflt. The function of the
mutation identified in exon3 (V202M) is still unclear, but concluding from previous
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studies, it could lead to inactivating the RET protein and thus impairing p170ret
expression at the plasma membrane.
4.1.1.1.2. Cystein-rich region (exons 7-10)
A high frequency of mutations in the cystein residues is often associated with
diseases such as MEN 2A and FMTC (95% of cases) (Mulligan et a/ 1993, Donis-
Keller et a/1993). Most mutations giving rise to these phenotypes are located in exon
10 (codons 609, 611, 618, 620 and 634) and include substituting cystein for a single
amino acid in the RET protein. A novel mutation in exon 7 (E480K), located in the
cystein rich area were identified in three males with aganglionosis restricted to the
distal part of the colon. This mutation did not, however, alter one of the cystein
residues. The mutations identified in MEN 2A, altering cystein residues, were shown
to activate RET function, resulting in tumorigenesis.
4.1.1.2. Transmembrane domain
The function of the transmembrane domain is to anchor the receptor in the cell
membrane and is involved in regulating cell growth and differentiation (Hëppener and
Lips 1996). A novel splice site mutation in the vicinity of the transmembrane region
(IVS10-2NG) was identified in a male with aganglionosis restricted to the
rectosigmoid area. Efficient splicing depends on accurate cleavage and rejoining,
which appears to be determined by the GT and AG dinucleotides present at the 5'
and 3' exon/intron boundaries, respectively. The splice variant might therefore
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interfere with the correct processing of the primary transcript and impair anchoring of
the receptor to the cell membrane.
4.1.1.3. Intracellular domain
The intracellular domain transduces the biological signal from the extracellular
domain into a biochemical message to intracellular target proteins (Hëppener and
Lips 1996). The intracellular domain consists of two tyrosine kinase regions, that is
the most highly conserved area of the gene. Mutation analysis of RET indicated that
mutations in the intracellular domain resulted in impairing tyrosine kinase activity.
4.1.1.3.1. Tyrosine kinase domain 1 and 2
By producing particular tyrosine kinase molecules and transducer molecules, specific
biological responses are allowed in different cell types. The tyrosine kinase region
plays an important role in tyrosine phosphorylation and substrate binding.
Phosphorylation on tyrosine residues is the result of ligand-induced receptor
dimerisation by a cross-phosphorylation mechanism. After phosphorylation,
cytoplasmic target molecules, containing a so-called src homology 2 (SH2) domain,
bind to specific phosphotyrosine-containing peptide sequences of the receptor
molecules. The substrate molecules are then phosphorylated on the tyrosine
residues, followed by transducing the signal further downstream and causing a
cellular response (Illustrated in figure 4.2) (H6ppener and Lips 1996).
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Figure 4.2. Dimerisation model for receptor tyrosine kinase activation (from
Hëppener and Lips 1996)
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The point mutations identified in exon 13 (D771 N) and exon 17 (P973L) reside in the
split tyrosine kinase region of the RET proto-oncogene. The mutation in exon 17,
substituting a proline (CCA) for a leucine (CTA), was previously described by Yin et
al (1994), who speculated that this missense mutation might result in the inactivation
of RET because of the substitution of amino acids in an area which is highly
conserved and these mutations might have a loss-of-function effect. A rare variant
identified in intron 16 (IVS 16-38deIG) was present in the same individual with the
mutation in exon 17 (P973L). This variant, although absent in 104 control subjects, is
thought to have no effect on the protein, even though it segregates with the mutation,
supporting linkage disequilibrium.
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thought to have no effect on the protein, even though it segregates with the mutation,
supporting linkage disequilibrium.
A splice variant (IVS19-9CIT) was identified in one individual with aganglionosis
restricted to the distal part of the colon. Introns, or the non-coding region of the gene,
are removed by a cleavage/ligation reaction before the mRNA is transported to the
cytoplasm for translation. This cleavage or ligation reaction is a highly accurate
process. Krawczak et a/ (1992) estimated that 15% of all point mutations in an intron
result in a mRNA splicing defect, causing human disease. Efficient splicing is
dependent on accurate cleavage and rejoining which appears to be determined by
the GT and AG dinucleotide present at the 5' and 3' exon/intron boundaries,
respectively. However, these sequence motifs are not the only determinants of
accurate splicing (Breathnach and Chambon 1981, Mount 1982, Padgett et a/1986).
Padgett et a/ (1986) derived the following consensus sequences:
5' (donor) splice site consensus sequence
-4 -3 -2 -1 +1 +2 +3
C2g/A34C3f!fAJs ~2 G77 / G100 T100 A60
Exon Intron
+4 +5 +6
A?4 G84 Tso
3' (acceptor) splice site consensus sequence
-14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4
Y?8 Y81 Y83 Y89 Y8S Y82 Y81 Y86 Y91 Y8? N
-3 -2 -1 +1
C?8 A100 G100 / Gss
Intron Exon
Y=pyrimidine, N=any base, subscript numerals refer to percentage frequency of
occurrence.
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Splicing defects are a common cause of human disease resulting in the abolishment
or at least a reduction in the amount of mature mRNA generated. These splicing
defects could also result in an exon not being recognised (exon skipping) and
thereby exclude it from the mature mRNA transcript. The splice variant identified in
the intracellular region of the (IVS19-9CIT) might therefore impair or influence kinase
activity.
4.1.2. ENDOTHELIN-B RECEPTOR AND ENDOTHELIN-3 GENE
The EDNRB and EDN3 genes are relatively conserved between species and
mutations in these genes were shown to contribute mainly to a syndromic HSCR
phenotype (HSCR-Waardenburg syndrome). Previous studies performed concluded
that EDNRB mutations account for approximately 6% of HSCR cases (Chakravarti
1996). Mutations of the EDN3 gene were previously identified in only a few HSCR
cases (Hofstra et 8/1999) and were mainly associated with Waardenburg syndrome.
In this study, no disease-related mutations were identified in either EDNRB or EDN3.
Band aberrations identified in the EDNRB gene mutation screen most likely
represented neutral polymorphisms. Since none of the South African patients
presented with a HSCR-Waardenburg phenotype, the failure to identify mutations in
this gene in our panel of HSCR patients was not unexpected.
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4.1.3. GENERAL OBSERVATIONS
Previous studies have demonstrated that RET mutations contribute to 25% of all
HSCR cases, while mutations identified in this study contributed to 19% of HSCR
cases (Edery et al 1994a, Romeo et al 1994, Angrist et al 1995, Eng and Mulligan
1997). Clustering of mutations occurs in exon 10 (95%) in MEN 2A patients (Mulligan
et a/1995), and in exon 16 (93%) in MEN 2B and FMTC patients in the RET proto-
oncogene (Hofstra et a/1994), whereas in HSCR, no hotspot area is observed and
mutations occur throughout the gene (Edery et al 1994a, Romeo et al 1994). The
RET protein appears to play an important role in embryogenesis and tumorigenesis,
particularly in tissues of neural crest origin, serving to transduce signals for cell
growth and differentiation (Schuchardt et al 1994). RET regulates proliferation,
migration, differentation and survival of enteric ganglion cells or their neural crest
precursors and thus an insufficient functional RET protein would prevent these
processes to be performed (Santoro et al 1994, Borrello et al 1995). Studies
performed by Hëppener and Lips (1996) indicated that RET gene mutations in MEN
2A, MEN 2B and FMTC result in activating RET tyrosine kinase activity. In contrast to
these observations, mutations identified in HSCR individuals possibly cause
inactivation of RET tyrosine kinase activity, resulting in the loss or absence of
ganglion cells (Pasini et a/1995).
Individuals heterozygous for RET mutations may develop HSCR whereas no effect is
observed in heterozygous mice, suggesting a gene dosage effect in humans. Mice
homozygous for RET mutations demonstrate a HSCR phenotype (Schuchardt et al
1994). This could be due to other known or novel modifier genes having a greater
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effect in humans than in mice. Mutations identified in EDNRB and EDN3 were
previously shown to be involved in the pathogenesis of the disease. These genes,
together with RET, only explain 20%-25% of HSCR cases. Other genes, that have
not yet been identified, are therefore probably involved in the pathogenesis of HSCR.
In this study, a higher frequency of mutations in the RET proto-oncogene was
identified in males (9 of 10) than in females (1 of 10). No correlation could be made
between patients presenting with long segment disease and those with short
segment disease due to the lack of long segment disease patients (7 of 53) in our
study population. Different sections of the colon, including both aganglionic and
ganglionic segments, were obtained from four of the patients presenting with both
HSCR and Down's syndrome. HEX-SSCP analysis showed a difference in banding
patterns in RET and EDNRB for the different segments of the same individuals.
These abberations represented polymorph isms and when these polymorph isms were
identified in the aganglionic segments, they were absent in the ganglionic segments,
and vice versa. The presence or absence of these polymorph isms could possibly,
together with mutations in other genes, contribute to the disease phenotype.
The potential disease-related mutations in the RET proto-oncogene were identified in
28.6% of the coloured patients and in 14% of the white patients. No mutations were
identified in the black patients. Population-directed mutation screening may facilitate
an improved diagnosis of HSCR in the South African population.
Stellenbosch University http://scholar.sun.ac.za
75
4.2. CONCLUSION
Potential disease-related mutations were identified in 19% of patients in our study
cohort. All the mutations were identified in the RET proto-oncogene, being the major
susceptibility gene for HSCR. These mutations were not clustered in a particular area
of the gene, but occurred throughout the gene. No potential disease-causing
mutations were identified in the EDNRB and EDN3 genes and mobility-based
aberrations in the EDNRB gene represented polymorphisms. These genes are
mainly associated with a HSCR/Waardenburg (Shah-Waardenburg syndrome)
phenotype, not observed in the South African patients studied.
Further studies have to be performed to elucidate the role of the potential disease-
causing mutations identified in South African patients with HSCR. Failure to detect
mutations in 81% of patients can be ascribed to the heterogeneous nature of HSCR,
or limitations imposed by the HEX-SSCP mutation screening method (Kotze et al
1995) used. Although the combination of heteroduplex and SSCP analysis provides a
highly efficient method (>90%) to detect small mutations, large rearrangements
cannot be ruled out.
A higher frequency of mutations were identified in patients with sporadic
rectosigmoidal aganglionosis (17%) compared to previous literature of 7.9% in these
patients. Mutation frequency in patients with sporadic total colonic aganglionosis
(33.3%) was more or less the same as previously described (42.2%), although only a
few patients presented with long segment disease (13%) in this study (Seri et al
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1994). Potential disease-related mutations were identified in 28.6% of the coloured
patients and in 14% of the white patients, suggesting that screening for these
mutations may facilitate improved diagnosis of HSCR in the South African population.
Further studies need to be performed to elucidate the genetics of HSCR in patients
with no apparent RET, EDNRB and EDN3 disease-related mutations.
4.3. Future prospects
Further studies need to be performed to elucidate the role of the potential disease-
related RET mutations identified in sporadic HSCR cases in the South African
population. Delineation of the effects of these mutations on the protein structure
could broaden our understanding of the biological role of the RET proto-oncogene in
the differentiation of cells of neural crest origin.
Extension of mutation analysis to also include familial cases may lead to the
development of a comprehensive DNA test for HSCR in the diverse South African
population. Also, including more long segment disease patients could possibly lead
to the association of mutations with a specific length of aganglionosis.
Recently, more HSCR loci have been identified in a genome scan, which is estimated
to account for all HSCR cases (Bolk et al 1998). This data will be incorporated in
future studies to possibly explain the HSCR phenotype in patients who could not be
characterised at the molecular level. The putative HSCR-associated gene on
Stellenbosch University http://scholar.sun.ac.za
77
chromosome 21 would be a good candidate for mutation screening in the cohort of
patients presenting with both HSCR and Down's syndrome.
The identification of mutations in HSCR patients would in future lead to improved and
accurate counselling of individuals with HSCR and their families, and ultimately
contribute to optimal therapy targeted at the cause of the disease. The varying
penetrance of mutations associated with the HSCR phenotype represents a major
challenge in genetic risk assessment. HSCR can be considered a model for the
many complex disorders currently under investigation world-wide.
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